

Please type a sign(+) inside this box



PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No.	0609.4110001/REF/JUK
First Inventor or Application Identifier	Rudolph E. TANZI
Title	A Diagnostic Assay for Alzheimer's Disease: Assessment of Aβ Abnormalities
Express Mail Label No.	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 67]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the invention
 - Brief Summary of the invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawings (35 U.S.C. 113) [Total Sheets 26]
4. ☒ Oath or Declaration [Total Pages 2]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below]
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein
6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment and Submission of Sequence Listing
13. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
14. ☐ *Small Entity Statement(s) (PTO/SB/09-12) ☒ Statement filed in prior application, Status still proper and desired
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Other 37 C.F.R. § 1.136(a)(3) Authorization

Other
*NOTE FOR ITEMS 1 & 14. IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

☒ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No: 08/817,423

Prior application information: Examiner P. Duffy Group/Art Unit: 1645

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

NAME	STERNE, KESSLER, GOLDSTEIN & FOX P L L C				
	Attorneys at Law				
ADDRESS	Suite 600, 1100 New York Avenue, N W				
CITY	Washington	STATE	DC	ZIP CODE	20005-3934
COUNTRY	USA	TELEPHONE	(202) 371-2600	FAX	(202) 371-2540

NAME (Print/Type)	Judith U. Kim	Registration No. (Attorney/Agent)	40,679
SIGNATURE		Date	October 25, 1999

Burden Hour Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE (202) 371-2540, (202) 371-6566

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL

ERIC K. STEFFE
MICHAEL O. LEE
STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.

DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
NOEL B. WHITLEY
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
BRIAN S. ROSENBLUM

LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT*
PETER A. JACKMAN*
MOLLY A. MCCALL*
TERESA U. MEDLER*
JEFFREY S. WEAVER*

DONALD J. FEATHERSTONE**
KAREN R. MARKOWICZ**
GRANT E. REED**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
CAMERON H. TOUSI**
VINCENT L. CAPUANO**

ROBERT H. BENSON*
OF COUNSEL

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

October 25, 1999

WRITER'S DIRECT NUMBER:
(202) 371-2678

Assistant Commissioner for Patents
Washington, D.C. 20231

Box Patent Application

Re: U.S. Non-Provisional Utility Patent Application Under 37 C.F.R. § 1.53(b)
Appl. No. To be assigned; Filed: Herewith (October 25, 1999)
(Continuation of Appl. No. 08/817,423; Filed August 4, 1997)
For: **A Diagnostic Assay for Alzheimer's Disease:
Assessment of A β Abnormalities**
Inventors: TANZI *et al.*
Our Ref: 0609.4110001/REF/JUK

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. PTO Utility Patent Application Transmittal Form (PTO/SB/05);
2. PTO Fee Transmittal Form PTO/SB/17 (*in duplicate*);
3. U.S. Utility Patent Application entitled:

A Diagnostic Assay for Alzheimer's Disease: Assessment of A β Abnormalities
and naming as inventors:

Rudolph E. TANZI, Canton, MA;

Assistant Commissioner for Patents
October 25, 1999
Page 2

Ashley I. BUSH, Somerville, MA; and
Robert D. MOIR, Boston, MA

the application consisting of:

- a. A specification containing:
 - (i) 60 pages of description prior to the claims;
 - (ii) 6 pages of claims (34 claims);
 - (iii) a one (1) page abstract;
 - b. 26 sheets of drawings (Figures 1a, 1b, 1c, 1d, 1e, 2a, 2b, 2c, 3a, 3b, 4a, 4b, 5, 6a, 6b, 6c, 6d, 7a, 7b, 7c, 7d, 8a, 8b and 9-11);
 - c. A paper copy of the sequence listing;
 - d. A computer readable disk copy of the sequence listing;
 - e. A copy of the original executed Declaration, as filed in U.S. Appl. No. 08/817,423;
 - f. Our check No. 25744 for \$801.00 to cover:
\$380.00 filing fee for patent application;
\$421.00 fee for excess claims;
4. Preliminary Amendment and Submission of Sequence Listing;
 5. A copy of original executed Statement Claiming Small Entity Status, as filed in U.S. Appl. No. 08/817,423;
 6. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (*in duplicate*); and
 7. Two (2) return postcards.


It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

Assistant Commissioner for Patents
October 25, 1999
Page 3

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Judith U. Kim
Attorney for Applicants
Registration No. 40,679

REF/JUK/lam
Enclosures

P:\USERS\JKIM\0609\411-1\Pto\cont tm

Statement Claiming Small Entity Status
(37 C.F.R. §§ 1.9(e) and 1.27(d)) -- Nonprofit Organization)

Applicant or Patentee: Rudolph E. TANZI, Ashley I. BUSH and Robert D. MOIR

Appl. or Patent No.: 08/817,423

Attorney Docket No. 0602.4110000/REP/TJK

Filed or Issued: 35 U.S.C. § 102(c) Date: August 4, 1997

For: A Diagnostic Assay for Alzheimer's Disease: Assessment of AB Abnormalities

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION THE GENERAL HOSPITAL CORPORATION

ADDRESS OF NONPROFIT ORGANIZATION 55 Fruit Street

Boston, Massachusetts 02114

TYPE OF NONPROFIT ORGANIZATION

- ☐ University or other institution of higher education
☒ Tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3))
☐ Nonprofit scientific or educational under statute of state of The United States of America
(Name of state _____)
(Citation of statute _____)
☐ Would qualify as tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3)) if located in The United States of America
☐ Would qualify as nonprofit scientific or educational under statute of state of The United States of America if located in The United States of America
(Name of state _____)
(Citation of statute _____)

I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. § 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

I hereby state that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention must file a separate statement indicating their status as small entities and that no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern or organization having any rights in the invention (other than the nonprofit organization named above) is listed below:

- ☐ no such person, concern, or organization exists.
☒ each such person, concern, or organization is listed below:

NAME Prana Corporation Pty. Ltd.

ADDRESS A.C.N. 080 699 065, 58-60 Essex Street, Collingwood 3066, Australia

() INDIVIDUAL (X) SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

NAME OF PERSON SIGNING David J. Glass, Ph.D.

TITLE IN ORGANIZATION Associate Director for Patents

ADDRESS OF PERSON SIGNING 13th Street, Building 149, Charleston, MA 01829

SIGNATURE [Signature]

DATE 6/22/99

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

1100 New York Avenue, N.W. • Suite 600 • Washington, DC 20005-3934 • (202) 371-2600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

TANZI *et al.*

Appl. No. To be assigned

Filed: Herewith (October 25, 1999)

For: **A Diagnostic Assay for
Alzheimer's Disease: Assessment
of A β Abnormalities**

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 0609.4110001/REF/JUK

Preliminary Amendment and Submission of Sequence Listing

Assistant Commissioner for Patents
Washington, D.C. 20231

Box: Patent Application

Sir:

In advance of prosecution, please enter the following amendments:

In the Specification

Page 1, line 20, please delete "proteina" and replace with --protein--; and

line 21, after "found" please insert --in--.

Page 16, at line 15, after "human A β peptide" please insert --(SEQ ID NO: 1)--.

Page 18, line 28, please delete "dissolving" and replace with --dissolving--.

After page 60, please insert pages 61 and 62 attached hereto, which contain the sequence listing for the subject invention. Please renumber the remaining pages accordingly.

In the Claims

Please rewrite claims 1 and 2 as follows:

1. (Once Amended) An [diagnostic] assay for detecting [and/]or quantifying A β peptide which may be present in a candidate solution, comprising:

(a) contacting the candidate solution with a solid support with a heavy metal cation immobilized thereon to capture A β peptide on the surface of the solid support, thereby forming a first complex which comprises solid support/heavy metal cation/A β peptide;

- (b) blocking all exposed metal binding sites remaining after A β capture with a blocker;
- (c) contacting the first complex, which has been passed through step (b), with a[n] polyclonal antibody specific for A β peptide to form a second complex which comprises solid support/heavy metal cation/A β peptide/polyclonal antibody specific for A β peptide;
- (d) labelling the second complex to form a detectable third complex which comprises solid support/heavy metal cation/A β peptide/polyclonal antibody specific for A β peptide/label; and
- (e) detecting the third complex, and quantifying A β peptide which may be present in the candidate solution.

2. (Once amended) An [diagnostic] assay for detecting [and/]or quantifying A β peptide which may be present in a candidate solution, comprising:

- (a) contacting the candidate solution with a solid support with a heavy metal cation immobilized thereon to capture A β peptide on the surface of the solid support, thereby forming a first complex which comprises solid support/heavy metal cation/A β peptide;
- (b) blocking all exposed metal binding sites remaining after A β capture with a blocker;
- (c) contacting the first complex, which has been passed through step (b), with a[n] polyclonal antibody specific for A β peptide, called A β antibody, to form a second complex which comprises solid support/heavy metal cation/A β peptide/A β antibody;

(d) contacting said second complex with one or more anti-antibodies specific to the A β antibody to form a third complex which comprises solid support/heavy metal cation/A β peptide/A β antibody/one or more anti-antibodies;

(e) labelling said third complex to form a detectable fourth complex which comprises solid support/heavy metal cation/A β peptide/A β antibody/one or more anti-antibodies/label; and

(f) detecting the fourth complex, thereby quantifying A β peptide which may be present in the candidate solution.

Please amend claims 3-16, 18-22, 24-26 and 28-30 as follows:

Claims 3-16, line 1, please delete "A diagnostic" and replace with --The--.

Claims 18-22, line 1, please delete "A" and replace with --The--.

Claims 24-26, line 1, please delete "A" and replace with --The--.

Claims 28-30, line 1, please delete "A" and replace with --The--.

Remarks

Upon entry of the foregoing amendment, claims 1-34 are pending in the application, with 1, 2, 31 and 32 being the independent claims.

Explanation of Amendments

The specification has been amended for clarity and to correct typographical errors.

Claims 1 and 2 have been amended to recite "[a]n assay" in place of "[a] diagnostic assay."

Claims 3-16, 18-22, 24-26 and 28-30 have been amended to recite "[t]he assay" or "[t]he kit" in place of "[a] assay" or "[a] kit," respectively.

Claims 1 and 2 have also been amended to recite "polyclonal antibody." Support can be found, for example, at page 5, line 12.

The specification has been amended to direct the entry of this sequence listing between the specification and claims of the above-identified application and to provide a SEQ ID NO next to the specific sequence.

These changes are believed to introduce no new matter, and their entry is respectfully requested.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Judith U. Kim
Attorney for Applicants
Registration No. 40,679

Date: October 25, 1999

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

A Diagnostic Assay for Alzheimer's Disease: Assessment of A β Abnormalities

Background of the Invention

Statement as to Rights to Inventions Made Under Federally-Sponsored Research and Development

5

Part of the work performed during the development of this invention utilized U.S. Government Funds under Grants Nos. RO1 NS3048-03 and RO1 AG11899-01 from The National Institutes of Health (NIH). The government may have certain rights in this invention.

10

Field of the Invention

15

The purpose of this invention is to assay the quantity and quality of A β peptide in Alzheimer's disease (AD) and A β amyloidotic disorders related to Alzheimer's disease. Specifically, the invention proposes to achieve this end by enriching the peptide by capturing it from biological fluids such as plasma, serum, cerebrospinal fluid or urine with a zinc- or copper-chelated microwell plate, and then measuring the amounts of captured A β with specific anti-A β antibodies in an ELISA.

Related Art

20

Alzheimer's disease is characterized pathologically by the accumulation in the brain of A β protein. The A β proteina is a small peptide that is also found cerebrospinal fluid and plasma. Much evidence implicates the accumulation of A β in the pathogenesis of the disease, either as the neurotoxic agent itself or as a hallmark which accompanies neurotoxicity in the disorder.

25

A β accumulates as a highly insoluble deposit within neuronal tissues. It is desirable to discover a treatment which would reverse the deposition and relieve or arrest clinical deterioration.

Aggregation of A β in the brain is believed to contribute to the progressive dementia, characteristic of Alzheimer's disease (AD) and to the premature AD observed among Down's syndrome patients. A β , a 4.3-kDa peptide, is the principal constituent of the cerebral amyloid deposits, a pathological hallmark of Alzheimer's disease (AD) (Masters *et al.*, *Proc. Natl. Acad. Sci. USA* 82:4245-4249 (1985); Glenner & Wong, *Biochem. Biophys. Rev. Commun.* 120:885-890 (1984)). A β is derived from the much larger amyloid protein precursor (APP) (Kang *et al.*, *Nature* 325:733-736 (1987); Tanzi *et al.*, *Science* 235:880-884 (1987); Robakis *et al.*, *Proc. Natl. Acad. Sci. USA* 84:4190-4194 (1987); Goldgaber *et al.*, *Science* 235:877-880 (1987)), whose physiological function remains unclear. The cause of Alzheimer's disease remains elusive; however, the discovery of mutations of APP close to or within the A β domain (Goate *et al.*, *Nature* 349:704-706 (1991); Levy *et al.*, *Science* 248:1124-1126 (1990); Murrell *et al.*, *Science* 254:97-99 (1991); Hendricks *et al.*, *Nature Genet.* 1:218-221 (1992), linked to familial AD (FAD) (E. Levy *et al.*, *Science* 248:1124 (1990); A β Goate *et al.*, *Nature* 349:704 (1991); M. Chartier-Harlin *et al.*, *Nature* 353:844 (1991); J. Murrell, M. Farlow, B. Ghetti, M.D. Benson, *Science* 254:97 (1991); L. Hendricks *et al.*, *Nature Genet.* 1:218 (1992); M. Mullan *et al.*, *Nature Genet.* 1:345 (1992)), indicates that the metabolism of A β and APP is likely to be intimately involved with the pathophysiology of this disorder.

Alzheimer's disease affects 10% of individuals over the age of 60, however, the existence of A β deposits in 40% of the brains of normal individuals in their forties suggests an even larger subclinical prevalence. Hence, the disease process is likely to be very common, with individual thresholds of neuronal and functional reserve being responsible for the varying onset of clinical symptoms. The disease is debilitating, chronic, incurable and very expensive to treat and an effective prevention or therapy would have an enormous commercial market. However, there are no reliable biochemical markers for AD.

FAD patients with the "Swedish" APP mutation overproduce the soluble, secreted form of A β and suffer from early onset (<60 years) AD

(Citron *et al.*, *Nature* 360:672-674 (1992)). A potential neuropathogenic mechanism has been reported by Younkin and colleagues (Society for Neuroscience, *Mol. Genet. Med.* 3:95-137 (1993)) for the APP 717 mutations which account for 90% of the APP mutations causing FAD. These mutations apparently lead to an increase in the ratio of "long" A β (1-42) to A β (1-40). A β (1-40) is the predominant species in the cerebrospinal fluid (CSF), and is a relatively soluble peptide. A β (1-42) is significantly more amyloidogenic, and its overproduction relative to the 1-40 species appears to lead to early-onset AD in these patients. Therefore, levels of A β (1-40) and A β (1-42) in the cerebrospinal fluid (CSF), plasma, serum or urine may be expected to correlate with cerebral pathology in sporadic AD cases, the predominant clinical form of the disorder.

Two protocols currently exist for the estimation of A β levels in biological fluids. The first involves the immunoprecipitation of A β with specific anti-A β antibodies (e.g. Haass *et al.*, *Nature* 359:322-325 (1992); Citron *et al.*, *Nature* 360:672-674 (1992)), a technique which is, at best, semiquantitative. This technique was used in combination with western blotting to measure A β levels in CSF (Shoji *et al.*, *Science* 258:126-129 (1992)) but found no gross differences between AD and control specimens. A double antibody capture ELISA using monoclonal antibodies raised against A β appears to give specific A β quantification with a sensitivity limit at about 0.6 nM (Seubert *et al.*, *Nature* 359:325-327 (1992)).

The double antibody ELISA is more widely used and is the only described means of accurately quantifying A β . It has two important limitations. It requires an abundance of expensive antibody to coat the wells of microwell plates in order to capture the A β from the biological fluid. A second anti-A β antibody, at a higher dilution, is used to detect captured A β . The second limitation of the double-antibody capture ELISA technique for A β assay is that it requires a fluorescence-generating enzyme-conjugated detection antibody and a fluorescence microwell plate reader for the final step of the assay.

Fluorescence plate readers are highly specialized and expensive (about \$30,000, Millipore Cytofluor), which limits the accessibility of the technique. Fluorescence has been preferred over more versatile, and cheaper, chromogenic assays (e.g., horse radish peroxidase-conjugated detection antibody acting on a chromogenic substrate), because it lowers the limit of sensitivity allowing the measurement of A β at the levels found in biological fluids. No A β assay has been described where the development of a chromogenic substrate was measured by a visible-light microwell plate reader, a far less expensive instrument (e.g., \$8,000).

The A β species assay of the present invention will provide a rational basis to monitor response to putative treatments for AD, as well as providing early diagnostic information if clinical outcome studies validate the correlation of the A β levels in the blood or CSF with disease progression.

Summary of the Invention

It has now been found that A β strongly and specifically binds zinc and copper in a pH dependent manner. These binding properties of A β have been exploited in this invention to create a novel means of capturing A β from biological fluids with a zinc- or copper-treated microwell plate, as well as a novel means for the bulk chromatographic purification of A β from biological fluids.

An advantage of this new ELISA technique over the previously described double antibody capture ELISA is that it obviates the need for a capture antibody (saving reagents and expense) and, because zinc- and copper-mediated capture appears to be more efficient than immobilized antibody capture, it is over an order of magnitude more sensitive than the reported sensitivity of double antibody capture ELISA. Hence, the assay results with biological fluids can be achieved using cheaper chromogenic substrates, in conjunction with a visible-light microwell plate reader.

In the present invention, an assay is designed to quantify the amount of A β peptide present in a solution such as a biological fluid. To do so, a

solid substrate is used to which a zinc (II) and/or copper (II) complex is immobilized. Preferably, the metal is complexed with immobilized nitriloacetic acid. The substrate is then contacted with the biological fluid. The free coordination sites on the zinc or copper atom act as a capture trap for A β peptide which can then be detected and quantified in a number of different ways.

The levels of A β are believed to correlate with the cerebral pathology of AD. However, the more highly amyloidogenic 1-42 species of A β may be more important in AD pathology than other species such as the 1-40 form. The present invention allows levels of the different species of A β to be measured by use of antibodies that are specific to 1-42 species and do not recognize the 1-40 form. Such antibodies are produced preferably from mice (although they may be produced from Guinea pigs, rabbits, rats, goats, sheep, horses, *et cetera.*) by injection with peptides containing the unique 40-42 region of the 1-42 species (peptides comprising the A β sequence from residue 42 to any residue less than 38 are suitable immunogens). A monoclonal antibody that is specific to the 1-42 species of A β may be selected by testing for immunoreactivity to different A β species that have been immobilized on a zinc or copper treated microwell plate.

Therefore, the first aspect of the invention relates to a diagnostic assay for detecting and/or quantifying A β peptide which may be present in a candidate solution, comprising:

(a) contacting the candidate solution with a solid support with a heavy metal cation immobilized thereon to capture A β peptide on the surface of the solid support, thereby forming a first complex which comprises solid support/heavy metal cation/A β peptide;

(b) blocking all exposed metal binding sites remaining after A β capture with a blocker;

(c) contacting the first complex, which has been passed through step (b), with an antibody specific for A β peptide to form a second complex which comprises solid support/heavy metal cation/A β peptide/antibody specific for A β peptide;

(d) labelling the second complex to form a detectable third complex which comprises solid support/heavy metal cation/A β peptide/antibody specific for A β peptide/label; and

(e) detecting the third complex, and quantifying A β peptide which may be present in the candidate solution.

A second aspect of the invention relates to a diagnostic assay for detecting and/or quantifying A β peptide which may be present in a candidate solution, comprising:

(a) contacting the candidate solution with a solid support with a heavy metal cation immobilized thereon to capture A β peptide on the surface of the solid support, thereby forming a first complex which comprises solid support/heavy metal cation/A β peptide;

(b) blocking all exposed metal binding sites remaining after A β capture with a blocker;

(c) contacting the first complex, which has been passed through step (b), with an antibody specific for A β peptide, called A β antibody, to form a second complex which comprises solid support/heavy metal cation/A β peptide/A β antibody;

(d) contacting said second complex with one or more anti-antibodies specific to the A β antibody to form a third complex which comprises solid support/heavy metal cation/A β peptide/A β antibody/one or more anti-antibodies;

(e) labelling said third complex to form a detectable fourth complex which comprises solid support/heavy metal cation/A β peptide/A β antibody/one or more anti-antibodies/label; and

(f) detecting the fourth complex, thereby quantifying A β peptide which may be present in the candidate solution.

The preferred heavy metal cations used in the practice of the present invention are zinc (II) or copper (II) complexed to nitriloacetic acid. Other organic ligands which may be used to complex the heavy metal, e.g. copper and zinc, are, but not limited to, iminodiacetic acid, tris(carboxymethyl)ethylenediamine, N,N,N,N,N-carboxy(methyl)tetraethylenepentamine,

and methionine-polyethyleneglycol (for other such compounds, *see* F.H. Arnold, *Biotechnology* 9:151-156 (1991), *e.g.*, at page 154).

The preferred antibodies used in the practice of the invention are those that are either specific to $A\beta_{1-42}$ which do not cross react with $A\beta_{1-40}$ or specific to $A\beta_{1-40}$ which do not cross react with $A\beta_{1-42}$.

In the preferred embodiments of the invention, the antibodies specific to $A\beta$ protein are labelled with a radioisotope (radioactive isotope), which can then be determined by such means as the use of a gamma counter or a scintillation counter. Isotopes which are particularly useful for the purpose of the present invention are: 3H , ^{125}I , ^{131}I , ^{32}P , ^{35}S , ^{14}C , ^{51}Cr , ^{36}Cl , ^{57}Co , ^{58}Co , ^{59}Fe and ^{75}Se . In other preferred embodiments of the invention, the antibodies specific to $A\beta$ protein are labelled by conjugating them to enzymes which can be detected when conjugated to said antibody, such as, but not limited to, fluorescence-generating enzymes, as well as chromogenic enzymes like alkaline phosphatase, urease, and horseradish peroxidase.

The body fluids that are assayed by the diagnostic assays of the present invention, are preferably pretreated as described in the Examples.

Another aspect of the invention relates to kits for carrying out the aforementioned assays which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon and a second container means containing an antibody specific for $A\beta$ peptide.

A further aspect of the invention relates to kits for carrying out the above-mentioned assays, which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing an antibody specific for $A\beta$ protein, and a third container means containing an anti-antibody which is specific for the antibody in the second container means. Preferably, the anti-antibody is detectably labeled.

A further aspect of the invention relates to kits preferably used for carrying out the above-mentioned assays with biological fluids, which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing an antibody specific for A β protein, a third container means containing an anti-antibody which is specific for the antibody in the second container means, and a fourth container means containing a methylating compound.

Another aspect of the invention relates to kits preferably used for carrying out the above-mentioned assays with biological fluids, which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing an antibody specific for A β protein, a third container means containing an anti-antibody which is specific for the antibody in the second container means, a fourth container means containing a methylating compound, and a fifth container means containing magnesium chloride.

Another aspect of the invention relates to kits preferably used for carrying out the above-mentioned assays with biological fluids, which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing an antibody specific for A β protein, a third container means containing an anti-antibody which is specific for the antibody in the second container means, a fourth container means containing a methylating compound, a fifth container means containing magnesium chloride, and a sixth container means containing a blocker.

Yet, another aspect of the invention relates to kits for carrying out the assays of the present invention which comprises a carrier means, compartmentalized in close confinement therein to receive one or more

container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon and a second container means containing a labelled antibody specific for A β protein.

5 Another aspect of the invention relates to kits preferably used for carrying out the assays of the present invention with biological fluids which comprises a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing a labelled antibody specific for A β protein, and a third container means containing a methylating compound.

10 A further aspect of the invention relates to kits preferably used for carrying out the assays of the present invention with biological fluids which comprises a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing a labelled antibody specific for A β protein, a third container means containing a methylating compound, and a fourth container means containing magnisium chloride.

20 Another aspect of the invention relates to kits preferably used for carrying out the assays of the present invention with biological fluids which comprises a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing a labelled antibody specific for A β protein, a third container means containing a methylating compound, a fourth container means containing magnisium chloride, and a fifth container means containing a blocker.

25 The next aspect of the invention relates to kits for carrying out the aforementioned assays which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy

30

metal cation immobilized thereon and a second container means containing an antibody specific for A β protein bound to a labelled anti-antibody.

Another aspect of the invention relates to kits preferably used for carrying out the aforementioned assays with biological fluids which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing an antibody specific for A β protein bound to a labelled anti-antibody, and a third container means containing a methylating compound.

A further aspect of the invention relates to kits preferably used for carrying out the aforementioned assays with biological fluids which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing an antibody specific for A β protein bound to a labelled anti-antibody, a third container means containing a methylating compound, and a fourth container means containing magnesium chloride.

A further aspect of the invention relates to kits preferably used for carrying out the aforementioned assays with biological fluids which comprise a carrier means, compartmentalized in close confinement therein to receive one or more container means, which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon, a second container means containing an antibody specific for A β protein bound to a labelled anti-antibody, a third container means containing a methylating compound, a fourth container means containing magnesium chloride and a fifth container means containing a blocker.

Another aspect of the invention relates to a method for purification of A β peptide from biological fluids containing one or more proteins which comprises:

- (a) methylating cysteine groups of the proteins in the biological fluid;
- (b) acidifying the biological fluid obtained from step (a);
- (c) applying the biological fluid obtained from step (b) to a copper-charged chelating-Sepharose column;
- (d) washing the column with equilibration buffer to obtain an eluate solution; and
- (e) collecting the eluate solution, thereby obtaining purified A β peptide.

Another aspect of the invention relates to a method for purification of A β peptide from biological fluids containing one or more proteins which comprises:

- (a) methylating cysteine groups of the proteins in the biological fluid;
- (b) acidifying the biological fluid obtained from step (a);
- (c) adding to the biological fluid obtained from step (b), a free copper-charged chelating slurry to form a mixture;
- (d) centrifuging the mixture obtained from step (c) to obtain a pellet;
- (e) washing the pellet obtained from step (d) with equilibration buffer, thereby obtaining purified A β peptide.

A further aspect of the invention relates to a kit for carrying out the method for bulk purification of A β peptide in biological fluids which comprises a carrier means compartmentalized in close confinement therein to receive one or more container means which comprises a first container means containing a copper charged chelating-Sepharose column and a second container means containing an antibody specific for A β peptide which may be used to confirm presence of purified A β peptide.

Finally, another aspect of the invention relates to a kit for carrying out the method of purifying A β peptide from biological fluids which comprises a carrier means compartmentalized in close confinement therein to receive one or more container means which comprises a first container means containing

free copper-charged chelating-Sepharose and a second container means containing an antibody specific for A β peptide which may be used to confirm presence of purified A β peptide.

Brief Description of the Figures

5 FIGs. 1a, 1b, 1c, 1d and 1e depict graphs showing analyses of
6⁵Zn²⁺ binding to A β . Values shown are means \pm S.D., $n \geq 3$. (1a)
Scatchard plot. Aliquots of A β were incubated (60 min) with ⁶⁵Zn²⁺ in the
presence of varying concentrations of unlabeled Zn²⁺ (0.01-50 μ M total). The
10 proportion of ⁶⁵Zn²⁺ binding to immobilized peptide (1.0 nmol) described two
binding curves as shown. The high-affinity binding curve has been corrected
by subtracting the low-affinity component, and the low-affinity curve has had
the high-affinity component subtracted. (1b) Bar graph showing the
specificity of the Zn²⁺ binding site for metals. A β was incubated (60 min)
with ⁶⁵Zn²⁺ (157 nM, 138,000 cpm) and competing unlabeled metal ions (50
15 μ M total). (1c) Bar graph showing ⁶⁵Zn²⁺ (74 nM, 104,000 cpm) binding to
negative (aprotinin, insulin a-chain, reverse peptide 40-1) and positive (bovine
serum albumin (BSA)) control proteins and A β fragments (identified by their
residue numbers within the A β sequence, *gln11* refers to A β ₁₋₂₈ where residue
11 is glutamine). Percent binding of total counts ⁶⁵Zn²⁺/min added is
20 corrected for the amounts (in nanomoles) of peptides adhering to the
membrane. (1d) Scatchard plot. As for (1a), with A β ₁₋₂₈ peptide substituting
for A β ₁₋₄₀. 157 nM ⁶⁵Zn (138,000 cpm) is used in this experiment to probe
immobilized peptide (1.6 nmol). (1e) Graph showing the pH dependence of
⁶⁵Zn²⁺ binding to A β ₁₋₄₀.

25 FIGs. 2a, 2b and 2c depict graphs showing effect of Zn²⁺ and other
metals on A β polymerization using G50 gel filtration chromatography.
Results shown are indicative of $n \geq 3$ experiments where 55 μ g of A β is
applied to the column and eluted in 15 ml, monitored by 254 nm absorbance.
(2a) A graph showing the chromatogram of A β in the presence of EDTA, 50
30 μ M, Zn²⁺, 0.4 μ M; Zn²⁺, 25 μ M; and Cu²⁺, 25 μ M. The elution points of

molecular mass standards and relative assignments of A β peak elutions are indicated. Mass standards were blue dextran (2×10^6 daltons, V_0 = void volume), BSA (66 kDa), carbonic anhydrase (29 kDa), cytochrome *c* (12.4 kDa), and aprotinin (6.5 kDa). The mass of A β is 4.3 kDa. (2b) Bar graph showing the relative amounts (estimated from areas under the curve) of soluble A β eluted as monomer, dimer, or polymer in the presence of various metal ions (25 μ M), varying concentrations of Zn $^{2+}$ or Cu $^{2+}$ (the likelihood of Tris chelation is indicated by upper limit estimates), and EDTA. Data for experiments performed in the presence of copper were taken from 214 nm readings and corrected for comparison. (2c) Bar graph showing the effects of pre-blocking the chromatography column with BSA upon the recovery of A β species in the presence of zinc (25 μ M), copper (25 μ M), or chelator.

FIGs. 3a and 3b depict bar graphs showing A β binding to kaolin (aluminum silicate): effects of zinc (25 μ M), copper (25 μ M), and EDTA (50 μ M). (3a) Bar graph showing the concentration (by 214 nm absorbance) of A β remaining in supernatant after incubation with 10 mg of G50 Sephadex. (3b) Bar graph showing the concentration (by 214 nm absorbance) of A β remaining in supernatant after incubation with 10 mg of kaolin, expressed as percent of the starting absorbance.

FIGs. 4a and 4b depict a blot and a bar graph showing the effect of Zn $^{2+}$ upon A β resistance to tryptic digestion. (4a) A blot of tryptic digests of A β (13.9 μ g) after incubation with increasing concentrations of zinc (lane labels, in micromolar), stained by Coomassie Blue. Digestion products of 3.6 kDa (A β_{6-40}), and 2.1 kDa (A β_{17-40}), as well as undigested A β_{1-40} (4.3 kDa), are indicated on the *left*. The migration of the low molecular size markers (*STD*) are indicated (in kilodaltons) on the *right*. (4b) A bar graph showing $^{65}\text{Zn}^{2+}$ binding to A β tryptic digestion products. The blot was incubated with $^{65}\text{Zn}^{2+}$, the visible bands excised, and the bound counts for each band determined. These data are typical of $n = 3$ replicated experiments.

FIG. 5 depicts a graph showing a scatchard analysis of ^{65}Zn binding to rat A β_{1-40} . Dissolved peptides (1.2 nMol) were dot-blotted onto 0.20 μ PVDF membrane (Pierce) and competition analysis performed as

described in Example 1 (FIG. 1). Rat $A\beta_{1-40}$ and human $A\beta_{1-40}$ were synthesized by solid-phase Fmoc chemistry. Purification by reverse-phase HPLC and amino acid sequencing confirmed the synthesis. The regression line indicates a K_A of $3.8 \mu\text{M}$. Stoichiometry of binding is 1:1. Although the data points for the Scatchard curve are slightly suggestive of a biphasic curve, a biphasic iteration yields association constants of 2 and $9 \mu\text{M}$, which does not justify an interpretation of physiologically separate binding sites.

FIGs. 6a, 6b, 6c and 6d depict graphs showing the effect of zinc upon human, ^{125}I -human and rat $A\beta_{1-40}$ aggregation into $>0.2 \mu$ particles. Stock human and rat $A\beta_{1-40}$ peptide solutions ($16 \mu\text{M}$) in water were pre-filtered (Spin-X, Costar, 0.2μ cellulose acetate, 700g), brought to 100 mM NaCl, 20 mM Tris-HCl, pH 7.4 (buffer 1) \pm EDTA ($50 \mu\text{M}$) or metal chloride salts, incubated (30 minutes, 37°C) and then filtered again (700g, 4 minutes). The fraction of the $A\beta_{1-40}$ in the filtrate was calculated by the ratio of the filtrate OD_{214} (the response of the OD_{214} , titrated against human and rat $A\beta_{1-40}$ concentrations (up to $20 \mu\text{M}$ in the buffers used in these experiments), was determined to be linear) relative to the OD_{214} of the unfiltered sample. All data points are in triplicate, unless indicated. (6a) A graph showing the proportions of $A\beta_{1-40}$, incubated $\pm \text{Zn}^{2+}$ ($25 \mu\text{M}$) or EDTA ($50 \mu\text{M}$) and then filtered through 0.2μ , titrated against peptide concentration. (6b) A graph showing the proportion of $A\beta_{1-40}$ ($1.6 \mu\text{M}$) filtered through 0.2μ , titrated against Zn^{2+} concentration. ^{125}I -human $A\beta_{1-40}$ (^{125}I -human $A\beta_{1-40}$ was prepared according to the method in Mantyh *et al.*, *J. Neurochem* 61:1171 (1993) (15,000 CPM, the kind gift of Dr. John Maggio, Harvard Medical School) was added to unlabeled $A\beta_{1-40}$ ($1.6 \mu\text{M}$) as a tracer, incubated and filtered as described above. The CPM in the filtrate and retained on the excised filter were measured by a γ -counter. (6c) A bar graph showing the proportion of $A\beta_{1-40}$ ($1.6 \mu\text{M}$) filtered through 0.2μ following incubation with various metal ions ($3 \mu\text{M}$). The atomic number of the metal species is indicated. (6d) A graph showing the effects of Zn^{2+} ($25 \mu\text{M}$) or EDTA ($50 \mu\text{M}$) upon kinetics of human $A\beta_{1-40}$ aggregation measured by 0.2μ filtration. Data points are in duplicate.

FIGs. 7a, 7b, 7c and 7d depict bar graphs showing the size estimation of zinc-induced A β aggregates. (7a and 7b) Bar graphs showing the proportion of A β_{1-40} (1.6 μ M in 100 mM NaCl, 20 mM Tris-HCl, pH 7.4 (buffer 1), incubated \pm Zn $^{2+}$ (25 μ M) or EDTA (50 μ M) and then filtered through filters of indicated pore sizes (Durapore filters (Ultrafree-MC, Millipore) were used for this study, hence there is a slight discrepancy between the values obtained with the 0.22 μ filters in this study compared to values obtained in FIG. 6 using 0.2 μ Costar filters). (7c) A bar graph showing $^{65}\text{ZnCl}_2$ (130,000 CPM, 74 nM) used as a tracer of the assembly of the zinc-induced aggregates of human A β_{1-40} produced in FIGs. 7a and 7b. By determining the amounts of A β_{1-40} and ^{65}Zn in the filtrate, the quantities retarded by the filters could be determined, and the stoichiometry of the zinc: A β assemblies estimated. (7d) Bar graph. Following this procedure, the filters, retaining Zn: A β assemblies, were washed with buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4) + EDTA (50 μ M x 300 μ l, 700g, 4 minutes). The amounts of zinc-precipitated A β_{1-40} resolubilized in the filtrate fraction were determined by OD $_{214}$, and expressed as a percentage of the amount originally retained by the respective filters. ^{65}Zn released into the filtrate was measured by γ -counting.

FIGs. 8a and 8b are photographs showing zinc-induced tinctorial amyloid formation. (8a) Zinc-induced human A β_{1-40} precipitate stained with Congo Red. The particle diameter is 40 μ . A β_{1-40} (200 μ l x 25 μ M in buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4)) was incubated (30 minutes, 37°C) in the presence of 25 μ M Zn $^{2+}$. The mixture was then centrifuged (16,000g x 15 minutes), the pellet washed in buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4) + EDTA (50 μ M), pelleted again and resuspended in Congo Red (1% in 50% ethanol, 5 minutes). Unbound dye was removed, the pellet washed with buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4) and mounted for microscopy. (8b) The same aggregate visualized under polarized light, manifesting green birefringence. The experiment was repeated with EDTA (50 μ M) substituted for Zn $^{2+}$ and yielded no visible material.

FIG. 9 depicts a graph showing the effect of zinc and copper upon human, ^{125}I -human and rat $\text{A}\beta_{1-40}$ aggregation into $>0.2\ \mu$ particles. Stock human and rat $\text{A}\beta_{1-40}$ peptide solutions ($16\ \mu\text{M}$) in water were pre-filtered (Spin-X, Costar, $0.2\ \mu$ cellulose acetate, 700g), brought to $100\ \text{mM}$ NaCl, $20\ \text{mM}$ Tris-HCl, pH 7.4 (buffer 1) \pm EDTA ($50\ \mu\text{M}$) or metal chloride salts, incubated (30 minutes, 37°C) and then filtered again (700g, 4 minutes). The fraction of the $\text{A}\beta_{1-40}$ in the filtrate was calculated by the ratio of the filtrate OD_{214} (the response of the OD_{214} , titrated against human and rat $\text{A}\beta_{1-40}$ concentrations (up to $20\ \mu\text{M}$ in the buffers used in these experiments), was determined to be linear) relative to the OD_{214} of the unfiltered sample. All data points are in triplicate, unless indicated. (FIG. 9) The graph shows the proportions of $\text{A}\beta_{1-40}$, incubated \pm Zn^{2+} ($25\ \mu\text{M}$) or Cu^{2+} or EDTA ($50\ \mu\text{M}$) and then filtered through $0.2\ \mu$, titrated against peptide concentration.

FIG. 10 depicts the amino acid sequence of human $\text{A}\beta$ peptide. The amino acid sequence of human $\text{A}\beta$ peptide is depicted and amino acid positions are numbered.

FIG. 11 depicts a standard curve graph for increasing $\text{A}\beta$ concentration on an ELISA using a copper coated 96-well plate for solid phase capture. Values are shown \pm S.D. $n = 3$. Increasing concentrations of $\text{A}\beta$ were prepared in coating buffer (Tris $20\ \text{mM}$, pH 7.4 and NaCl $150\ \text{mM}$). Aliquots ($200\ \mu\text{l}$) were transferred to the wells of a copper-treated 96-well plate ((copper (II) was immobilized on the well surface with nitriloacetic acid) and incubated for 2 h at 37°C . The solution in the wells was removed and replaced with $300\ \mu\text{l}$ per well of blocking buffer (2% gelatin in Tris $20\ \text{mM}$, pH 8 and NaCl $150\ \text{mM}$) and the plate incubated at 37°C for a further 2 h. The wells were washed two times with $300\ \mu\text{l}$ aliquot's of washing buffer (Tris $20\ \text{mM}$, pH 8 and NaCl $150\ \text{mM}$) before being incubated (2 h at 37°C) with a primary antibody ($200\ \mu\text{l}$ per well of antibody diluted 1/1000 with blocking buffer containing a reduced gelatin concentration (0.2%)) directed at the N-terminus of $\text{A}\beta$ (a now commercially available mouse monoclonal antibody supplied by Dr. S.K. Kim of the NY State Institute for Basic Research in Developmental Disabilities). The wells were

washed three times with washing buffer before the addition of anti-mouse-antibody-HRPO conjugate (200 μ l per well of a 1/1000 dilution in 0.2% gelatin blocking buffer) and a final incubation at 37°C for 2 h. The wells were washed three times with washing buffer and one final rinse in water before the addition of 200 μ l per well of HRPO substrate solution (Pierce, 34024). After a 30 minute incubation at room temperature (18-22°C) a 25 μ l aliquot of 2 M H₂SO₄ was added to each well and absorbance of the plate measured at 450 nm. The average background absorbance (wells containing no A β) was subtracted from the absorbance of A β standards and the resulting values plotted against peptide concentration.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Detailed Description of the Preferred Embodiments

A β ₁₋₄₀, the major component of Alzheimer's disease cerebral amyloid is relatively soluble at high concentrations (≤ 3.7 mM) and has been detected in CSF and blood. Physiological factors which decrease solubility and induce A β amyloid formation may be important in the pathogenesis of the disease. It has been discovered that human A β specifically and saturably binds zinc, and that concentrations of this metal ion above 300 nM rapidly destabilize human A β ₁₋₄₀ solutions, inducing tinctorial amyloid formation. High-affinity binding ($K_A = 107$ nM) compatible with normal CSF zinc levels, and low-affinity binding ($K_A = 5.2$ μ M) have now been shown. In contrast, rat A β ₁₋₄₀ binds zinc less avidly and does not aggregate in its presence, suggesting a possible explanation for lack of cerebral A β amyloid in these animals. Collectively, these data suggest a potentially critical role for cerebral zinc metabolism in the neuropathogenesis of Alzheimer's disease.

Further, it has been observed that abnormalities of zinc homeostasis occur in AD and DS patients. Cerebral zinc homeostasis, which has been reported to be abnormal in AD (D. Wenstrup, W.D. Ehmann, W.R. Markesbery, *Brain Res.* 533:125 (1990); J. Constantinidis, *Encephale* 16:231

(1990); F.M. Corrigan, G.P. Reynolds, N.I. Ward, *Biometals* 6:149 (1993); C.O. Hershey *et al.*, *Neurology* 33:1350 (1983)) may be important for the metabolic fate of A β since increased concentrations of zinc promote the peptide's adhesiveness and resistance to proteolytic digestion. Moreover, oral zinc supplementation has recently been shown to have an acutely adverse effect on cognition in AD subjects, but not age-matched controls indicated that environmental or nutritional zinc exposure may be a contributing factor to AD pathophysiology.

The present findings have indicated that A β strongly and specifically binds zinc in a pH dependent manner. In the brain milieu, these metal ions are present in sufficient concentration to exert these effects on binding and solubility. A decrease in A β solubility occurs in the presence of concentrations of zinc as low as 0.3 μ M. Occupation of the zinc binding site on A β increases the resistance of the peptide to tryptic digestion at the α -secretase site. α -Secretase is an, as yet, unidentified protease which has been observed to cleave the precursor molecule of A β , the Amyloid Protein Precursor (APP) within the A β domain, rendering A β incapable of accumulating. Hence, occupation of the zinc binding site on A β will increase the biological half-life of the peptide and so increase its availability for deposition.

The diagnostic assays of the present invention are carried out as exemplified in Example 14, below. In general, a commonly used protocol for an ELISA is followed. The A β peptide acts as the antigen of a conventional direct ELISA. The plates used are coated with zinc (II) or copper (II), hence, enabling the relatively stable binding of the A β peptide to the surface of the plate. Preferably, the zinc (II) or copper (II) is complexed to a ligand which is immobilized on the plate. Examples of such ligands include nitriloacetic acid and iminodiacetic acid. The complexes are prepared by dissolving the ligand in an organic solvent such as ether, depositing the solution on a solid support, letting the solvent evaporate, and then adding an aqueous solution of a zinc (II) or copper (II) salt (such as the chloride). The solid support may then be washed with additional solution to remove unreacted ligand and metal salt. Preferred solid supports include but are not limited to nitrocellulose,

diazocellulose, microtiter plates, glass, plastic, polystyrene, polyvinyl, polyvinylchloride, polypropylene, polyethylene, dextran, affinity support gels such as Sepharose or agar, starch, and nylon. Those skilled in the art will note that many other suitable carriers for binding the ligand exist, or will be able to ascertain the same by use of routine experimentation.

In a different embodiment of the diagnostic assays, the A β peptide in a solution can be detected by using solid support particles. The particles, beads or pieces of a solid support, are coated with zinc (II) or copper (II) form of nitriloacetic acid, thus, enabling the relatively stable binding of the A β peptide to the surface of the particle. The candidate solution is added to the particles and incubated as before-described to allow binding of the A β peptides to the surface(s) of the particles. Labelled antibodies, particularly radiolabelled ones, are used to bind to the A β peptides. Alternatively, antibodies specific for A β are added to bind to the A β peptides, and then labelled anti-antibodies, particularly radiolabelled ones, which are specific for the A β antibodies, are added to bind to the A β antibodies, thereby allowing detection and quantification of the A β peptides. The A β peptides are detected and/or quantified with the appropriate means, e.g., scintillation counter.

The bulk purification of A β from biological fluids is best achieved with copper charged chelating-Sepharose (Pharmacia, catalog no. 17-0575-01). The cysteine groups in the sample proteins are first methylated with N-methyl maleimide, about 1-20 mM, preferably, about 10-20 mM, and most preferably, about 10 mM for about 1-2 hours, preferably about 1 hour, (other appropriate compounds, such as, iminodiacetic acid, may be used instead of maleimide in similar concentrations and for similar periods of time), then acidified by titrating pH to about 4.9-5.0, preferably to about 5.0, using about 1-2 M, preferably about 1M, sodium acetate, pH about 3-4, preferably about 3.5, and the total NaCl concentration increased by about 450-550 mM, preferably by about 500 mM, with about 4-5 M, preferably about 5M NaCl. The sample is then applied to a copper-charged chelating-Sepharose column (e.g., 250 μ l bed volume for about 15 ml of CSF) or free copper-charged chelating-Sepharose slurry (about 50-60 μ l, preferably about

50 μ l of about 50% v/v) is added to the sample if the volume is less than about 4 ml. Equilibration buffer is about 450-550 mM, preferably about 500 mM NaCl about 25-100 mM, preferably about 50 mM MES, pH about 4.0-5.1, preferably about 5.0 and is used to wash the column or the Sepharose pellet following centrifugation (preferably, low speed centrifugation (about 1,200-1,800 g, preferably about 1,500 g, for about 2-4 minutes, preferably about 3 minutes)). It should be noted that as the speed of centrifugation increases, the centrifugation time decreases. The Sepharose pellet is developed with SDS sample buffer containing 50 mM EDTA if the sample is to be applied in entirety to western blot analysis. Alternatively, the Sepharose can be developed with about 450-550 mM, preferably about 500 mM NaCl, 50 mM EDTA, pH about 7.0-9.0, preferably about 8.0, alone and the eluate sampled for western blot analysis. The treatment of 15 ml of CSF by this method enriched both soluble APP as well as 4.3 and 3.6 kDa species of A β (identified by an antibody that identifies an epitope in the first 16 residues of A β ; commercially available). In order to bind copper or zinc, the peptide requires an intact domain from residues 6-28. 4G8 only recognized the two A β species and not APP, confirming that the APP captured by the Sepharose was post-secretase cleaved soluble APP. The use of specific anti-A β antibodies as described above on western blot analysis of these products can confirm the specificity of the ELISA immunoreactivity.

DEFINITIONS

A β peptide is also known in the art as A β , β protein, β -A4 and A4.

Amyloid as is commonly known in the art, and as is intended in the present specification, is a form of aggregated protein.

Similarly, A β Amyloid is an aggregated A β peptide. It is found in the brains of patients afflicted with AD and DS and may accumulate following head injuries and in Guamanian amyotrophic lateral sclerosis/Parkinson's dementia (GALS/PDC).

Tinctorial amyloid is referred to amyloid that in addition to being insoluble in aqueous buffer can be stained with Congo Red, and has positive birefringence in polarized light.

5 Anti-amyloidotic agent refers to a compound that inhibits formation of amyloid.

Zinc-induced A β aggregates are, like tinctorial amyloid, insoluble in aqueous buffer and stain with Congo Red.

10 A β amyloidosis, as is commonly known in the art and intended in the present specification, refers to the pathogenic condition in humans and other animals which is characterized by formation of A β amyloid in neural tissue such as brain.

15 Pre-filtering and pre-filtered as used in the present specification means passing a solution, e.g. A β peptide in aqueous solution, through a porous membrane by any method, e.g. centrifugation, drip-through by gravitational force, or by application of any form of pressure, such as gaseous pressure.

Physiological solution as used in the present specification means a saline solution which comprises compounds at physiological pH, about 7.4, which closely represents a bodily or biological fluid, such as CSF, blood, plasma, *et cetera*.

20 Heavy metal chealating agent refers to any agent, e.g., compound or molecule, which chelates heavy metals, i.e., binds the heavy metal very tightly and can inhibit or stop interaction with other agents. Examples of such heavy metal chealating agents are EDTA or Desferrioxamine.

25 In the present invention, the heavy metal salts are of any heavy metal or any transition metal, in any form, soluble or insoluble, e.g. the chloride, bromide, or iodide salts.

30 A blocker of heavy metal cations as used in the present invention refers to any compound that binds to all exposed metal binding sites remaining on the heavy metal cations, which are conjugated to the solid support, after A β capture. Examples of such blockers are, but are not limited to, gelatin (Biorad, catalog no. 170-6537) and SuperBlock (Pierce, catalog no. 375-35).

In the present specification, unless otherwise indicated, zinc means salts of zinc, i.e., Zn^{2+} in any form, soluble or insoluble.

5 Biological fluid means fluid obtained from a person or animal which is produced by said person or animal. Examples of biological fluids include but are not limited to cerebrospinal fluid (CSF), blood, serum, urine, and plasma. In the present invention, biological fluid includes whole or any fraction of such fluids derived by purification by any means, *e.g.*, by ultrafiltration or chromatography.

10 Neat sample of a biological fluid means that the biological fluid has not been altered by, for example, dilution.

Control human subject refers to a healthy person who is not afflicted with amyloidosis.

15 Synthetic peptide standard in the present invention means an assembly of amino acids linked by peptide bonds that is synthesized in a laboratory. Methods for making synthetic peptides include, although are not restricted to, such procedures as solid phase P_{moc} chemistry.

A candidate solution in the present invention means a solution which is suspected of containing $A\beta$ peptide.

20 An anti-antibody in the present invention means an antibody that binds specifically to another antibody. Generally such antibodies are obtained by immunizing an animal with the antibody from another animal. Thus, one can obtain goat anti-IgG polyclonal antibodies in this way.

25 A solid support in the present invention means any solid material to which the heavy metal cations can be complexed, and which can be used to make and use the invention. Examples of such solid support are, but not limited to, microtitre plates, petri dishes, bottles, slides, and other such containers made of plastic, glass, polyvinyl, polystyrene, and other solid materials which do not interfere with the formation of complexes and allow detection of labelled antibodies.

30 More specifically, solid support particles which may be used in the present invention are irregular shaped solid supports such as beads, particles,

and pieces of the aforementioned solid materials which may be used for the practice of the present invention.

Persons skilled in the art are able to screen for and determine the usefulness of a solid support material by parallel testing and comparison between the material in question and a known solid support material such as polyvinyl or polystyrene.

In the present invention, the A β peptide may be comprised of any sequence of the A β peptide as long as it contains at least the amino acids corresponding to positions 6 through 28 of A β peptide which comprise the binding site for zinc, the most preferred heavy metal cation capable of binding to a polypeptide comprising at least amino acids 6 to 28 of A β . The preferred embodiments of the invention make use of peptides A β ₁₋₃₉, A β ₁₋₄₀, A β ₁₋₄₁, A β ₁₋₄₂, and A β ₁₋₄₃. The most preferred embodiment of the invention makes use of A β ₁₋₄₀. However, any of the A β peptides which comprises at least amino acids 6 to 28 of A β may be employed according to the present invention. The sequence of A β peptide, including amino acids 6 to 28, is found in Fig. 10 (C. Hilbich *et al.*, *J. Mol. Biol.* 228:460-473 (1992)).

In the present method, the A β peptide is directly detected by using optical spectrophotometry. This is possible because a direct correlation exists between concentration of the peptide and OD₂₁₄ measurements. Although the preferred wave length for the OD measurements is about 214 nm, the measurements may be carried out for the purpose of the present invention at wave lengths from about 190 to about 500 nm. Preferred wave lengths are, however, from about 208 to about 280 nm.

Further, the A β peptide may be detected by radiolabelling the peptide and measuring the compounds per minute (CPM) of the filtrates and/or the pellets. A preferred radiolabelled A β peptide in the present invention is ³H-A β . Other radiolabels which can be used in the present invention are ¹⁴C and ³⁵S.

The labelled antibodies and anti-antibodies are detected by using visible-light microwell plate reader (for chromogenic enzymes), fluorescence microwell plate reader (for fluorescence-generating enzymes), and scintillation

counter (for radioisotopes). The types of labels and the appropriate means for detection of the labels, however, are not limited to those specifically mentioned herein.

5 Other heavy metal cations capable of binding to a polypeptide comprising at least amino acids 6 to 28 of A β which may be used in the practice of the invention include metallochloride salts, preferably of zinc, copper, or mercury. The most preferred embodiment of the invention, however, makes use of zinc chloride.

10 In the preferred embodiments of the invention, the antibodies specific to A β protein are labelled with a radioisotope (radioactive isotope), which can then be determined by such means as the use of a gamma counter or a scintillation counter. Isotopes which are particularly useful for the purpose of the present invention are: ^3H , ^{125}I , ^{131}I , ^{32}P , ^{35}S , ^{14}C , ^{51}Cr , ^{36}Cl , ^{57}Co , ^{58}Co , ^{59}Fe and ^{75}Se .

15 Another way in which the antibody of the present invention can be detectably labeled is by linking or conjugating the same to an enzyme. This enzyme, in turn, when later exposed to its substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected as, for example, by spectrophotometric, fluorometric or visual
20 means. Examples of enzymes which can be used to detectably label the antibody of the present invention include malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose
25 oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetylcholine esterase. Avidin-biotin binding may be used to facilitate the enzyme labeling.

It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave
30 length, its presence can then be detected due to the fluorescence of the dye. Among the most commonly used fluorescent labelling compounds are

fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

5 The antibody of the invention can also be detectably labeled using fluorescent emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody molecule using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

10 The antibody of the present invention also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

15 Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent antibody is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

20 Another technique which may also result in greater sensitivity when used in conjunction with the present invention consists of coupling the antibody of the present invention to low molecular weight haptens. The haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin (reacting with avidin) or dinitrophenyl, pyridoxal and fluorescamine (reacting with specific anti-hapten antibodies) in this manner.

25 In addition, the sensitivity of the assay may be increased by use of amplification strategies including substrate cycling and enzyme channeling as taught by Mosbach (Lindbladh *et al.*, *Trends in Biochem. Sci.* 18:279-283 (1993).

The pH of the reaction mixtures for A β capture to immobilized metal ions is, unless otherwise indicated, preferably close to neutral (about 7.4). The pH, therefore, may range from about 6.8 to about 8.5, preferably from about 7 to about 7.8, and most preferably about 7.4. The pH of other incubations, including antibody and anti-antibody incubations is between 7-9, preferably at 8.

Buffers which can be used in the methods of the present invention include, but are not limited to, Tris-chloride and Tris-base, MOPS, HEPES, bicarbonate, Krebs, and Tyrode's. The concentration of the buffers may be between about 10 mM and about 500 mM. However, considering that these buffers chelate zinc, the concentration of the buffers should be kept as low as possible without compromising the results.

The present invention permits use of very low concentrations of A β peptide, e.g. from about 0.1 nM to 3.7 mM (upper limit of solubility). A preferred embodiment of the invention employs about 0.8 nM concentration of A β peptide, the lowest detectable concentration of A β previously reported for an ELISA type assay was 0.5 nM (Schubert *et al.*, *Nature* 359:325-327 (1992)).

The present invention may be practiced at temperatures ranging from about 1 degree centigrade to about 99 degrees centigrade. The preferred temperature range is from about 4 degrees centigrade to about 40 degrees centigrade. The most preferred temperature for the practice of the present invention is about 37 degrees centigrade. Therefore, an advantage of the present invention is the greatest sensitivity over previous detection systems.

The A β peptide is trapped by the free coordination sites on the zinc or copper atoms (binds to the zinc or copper atoms) at near-instantaneous rate. However, defusion rates are a limiting factor in the absorption of the peptide and antibodies to the solid phase. In a preferred embodiment of the invention, the incubations are carried out for about 90-240, preferably about 120, minutes to maximize capture.

To determine whether A β binds zinc, a synthetic peptide representing secreted A β_{1-40} was incubated with $^{65}\text{Zn}^{2+}$. Rapid binding (60% B_{max} at

1 min), which plateaued at 1 h, was observed. Scatchard analysis of $^{65}\text{Zn}^{2+}$ binding describes two saturable binding curves, a high affinity curve ($K_a < 107 \text{ nM}$), and a lower affinity curve ($K_a < 5.2 \mu\text{M}$) (Fig. 1a). The affinity constant estimates might be skewed by assuming that the Tris buffer does not bind zinc. In fact, Tris-HCl binds zinc and copper with stability constants of 4.0 and 2.6, respectively (Dawson *et al.*, *Data for Biochemical Research*, Oxford University Press (1986)). Incubating A β in the presence of higher concentrations of Tris (150 and 500 mM) abolishes $^{65}\text{Zn}^{2+}$ binding to A β ($\approx 50\%$ and $\approx 95\%$, respectively), indicating that Tris-induced Zn^{2+} chelation cannot be excluded. Our calculated affinity constants are therefore upper limit estimates.

$^{65}\text{Zn}^{2+}$ binding is very specific, with Zn^{2+} being the only unlabeled metal ion tested that is capable of competing off the label (Fig. 1b). To determine the specific region of A β involved in zinc binding and to validate the dot-blot binding system, equivalent amounts of various peptides representing fragments of A β_{1-40} and peptide controls were assayed for $^{65}\text{Zn}^{2+}$ binding in this system (Figs. 1c and 1d).

The reverse sequence (40-1) control peptide only binds 50% of B_{max} compared with A β_{1-40} (Fig. 1c), indicating that zinc binding is not merely a consequence of the presence of favorable residues. A β_{1-28} bound 30% of B_{max} , indicating that the carboxyl terminus plays an important role in promoting zinc binding. Glutamine substitution for the glutamate at position 11 of A β_{1-28} , in accordance with the Down's syndrome A β sequence reported by Glenner and Wong, *Biochem. Biophys. Res. Commun.* 120:885-890 (1984), does not interfere with $^{65}\text{Zn}^{2+}$ binding. The Scatchard plot of $^{65}\text{Zn}^{2+}$ binding to A β_{1-28} reveals similar low-affinity ($K_a < 15 \mu\text{M}$) and high-affinity ($K_a < 334 \text{ nM}$) binding associations (Fig. 1d) to those of A β_{1-40} , but overall the A β_{1-28} peptide binds zinc less avidly. Although the A β_{1-28} peptide clearly binds zinc, peptides overlapping this region (1-17 and 12-28) do not individually bind zinc. Additionally, a peptide covering a region of the carboxyl terminus (25-35) also is unable to bind zinc (Fig. 1c).

The calculated stoichiometry of high-affinity Zn^{2+} -binding to $\text{A}\beta$, derived from the x-intercepts on the Scatchard plots (Fig. 1, *a* and *d*), is 0.7:1 ($\text{A}\beta_{1-40}$) and 1:4 ($\text{A}\beta_{1-28}$). For low-affinity binding, the Zn^{2+} : $\text{A}\beta$ ratio is 2.5:1 ($\text{A}\beta_{1-40}$) and 4:1 ($\text{A}\beta_{1-28}$).

$^{65}\text{Zn}^{2+}$ binding of sequenced tryptic digest products of $\text{A}\beta$ (Fig. 4b) indicates that the 6-40 fragment binds zinc, but that the other visible digest fragment 17-40 (Fig. 4b), equivalent to the post-secretase (Esch *et al.*, *Science* 248:1122-1124 (1990); Sisodia *et al.*, *Science* 248:492-495 (1990)) carboxyl-terminal product produced *in vivo*, does not bind zinc. The contribution of histidines (residues 6, 13, and 14) to Zn^{2+} binding is indicated by the deterioration of binding with lower pH (30% of B_{max} at pH 6.0, Fig. 1e). Taken together, these data indicate that zinc coordination requires the contiguous sequence between residues 6 and 28, a region containing all 3 histidine residues, and that optimal zinc binding also requires the presence of the carboxyl-terminal domain.

Further experiment investigated whether zinc binding could affect $\text{A}\beta$ conformation as assayed by migration on gel-filtration chromatography. Major $\text{A}\beta$ species believed to correspond to monomeric, dimeric, and polymeric forms were observed (Fig. 2a). Total concentrations of Zn^{2+} as low as $0.4 \mu\text{M}$ decrease recovery of $\text{A}\beta$ compared with elution profiles obtained in the presence of EDTA and other metals (Figs. 2a and 2b). At $25 \mu\text{M}$ total Zn^{2+} , <20% of the $\text{A}\beta$ applied to the column is eluted. The greatest loss occurred among high order polymer and dimeric species. The relative amount of monomeric $\text{A}\beta$ is less affected. A systematic assessment of several metals indicates that the reduction of $\text{A}\beta$ recoverable by chromatography is most sensitive to Zn^{2+} , with related transition metals Co^{2+} , Ni^{2+} , and Fe^{2+} (at $25 \mu\text{M}$) displaying similar effects on chromatography to those obtained with only $10 \mu\text{M}$ Zn^{2+} (Fig. 2b). Other transition metals, heavy metals, and Al^{3+} ($25 \mu\text{M}$) have partial effects on $\text{A}\beta$ solubility comparable with $3 \mu\text{M}$ total Zn^{2+} . Meanwhile, Ba^{2+} , Ag^{2+} , Mg^{2+} , and Ca^{2+} ($25 \mu\text{M}$) have the least effect on $\text{A}\beta$ compared with the EDTA profile, although a 60% reduction in eluted peptide was observed in the presence of

these metal ions. Pb^{2+} (25 μM) most strongly promotes the elution of the monomeric peptide, abolishing high order polymers; overall recovery is similar to that obtained with 0.4 μM total Zn^{2+} . In making comparisons of the effects of these metal ions, it is again important to consider the differential metal ion chelating effects of Tris previously mentioned.

A dramatic increase in $\text{A}\beta$ dimerization is observed with Cu^{2+} (25 μM total). This metal also induces exaggerated $\text{A}\beta$ absorbance (4-fold) at 254 nm when compared with 214 nm absorbance and induces the monomeric species to apparently fluoresce at 254 nm causing negative readings (Fig. 2a) which are proportionally positive at 214 nm (Fig. 2b). A higher concentration of Cu^{2+} (80 μM total) promotes increased recovery of $\text{A}\beta$, indicating that the presence of Cu^{2+} at relatively low concentrations (less than 25 μM) favors solubility in this system.

The metal ions which most favored $\text{A}\beta$ solubility (Mg^{2+} , 25 μM and total Cu^{2+} , 25 μM) were tested for their ability to stabilize $\text{A}\beta$ in a soluble state in the presence of 25 μM total Zn^{2+} . These combinations neither rescue nor worsen Zn^{2+} -induced loss of $\text{A}\beta$ recovery (Fig. 2b). Overall, these data suggest that Zn^{2+} reduces the recovery of $\text{A}\beta$, whereas a chelating agent attenuates this effect.

Chromatography of $\text{A}\beta$ was performed under various conditions to determine if zinc-induced loss of $\text{A}\beta$ could be blocked. Pretreating the column with 3% BSA as an adsorption blocker significantly increased the amounts of $\text{A}\beta$ recovered from the column, and suggest that on untreated apparatus the peptide precipitates onto a column component (Fig. 2c). Blocking the column results in a 200% increase in the recovery of $\text{A}\beta$ in the presence of Zn^{2+} (25 μM total), a 75% increase in recovery in the presence of Cu^{2+} (25 μM total), but only a 10% increase in the presence of EDTA (50 μM). This indicates that precipitation onto the column is most specifically accelerated by zinc.

To determine the part of the column onto which $\text{A}\beta$ was precipitating, $\text{A}\beta$ solutions were incubated with various column components and assayed by UV absorption before and after incubation. Replicating the chromatography

experimental conditions, A β (100 μ M in equilibration buffer) was incubated for 1 h in plastic reaction vessels with or without the presence of Sephadex. Loss to the plastic accounts for <5% of the observed precipitation, to siliconized plastic <1%, and binding to Sephadex <1%. Hence, A β precipitates are unlikely to be adsorbing to the Sephadex or plastic support. However, similar incubations in borosilicate glass test tubes result in 20% adsorption, which increase to 35% in the presence of zinc (25 μ M).

The glass in the Bio-Rad Econo Columns is made of 7740 Pyrex (Corning, Park Ridge, IL) and is composed of SiO₂, 80.6%; B₂O₃, 13.0%; Na₂O, 4.0%; and Al₂O₃, 2.3%. Previous workers have found evidence linking aluminosilicates with β -amyloid deposition (Masters *et al.*, *EMBO J.* 4:2757-2763 (1985a); Candy *et al.*, *Lancet* 1:354-357 (1986)). In light of these reports, experiments were performed to further investigate the phenomena which were observed for precipitation of A β on 7740 Pyrex glass. Rapid and extensive binding of A β to kaolin, an insoluble hydrated aluminum silicate was observed. Moreover, incubation of A β (0.4 mg/ml) with Sephadex (5%, v/v) in the presence of zinc, copper, or EDTA causes only small changes in solubility, some of which is probably due to binding of the peptide to the plastic reaction vessels (Fig. 3a). Incubation of A β (0.4 mg/ml) with kaolin (5%, v/v, 5 min, room temperature), causes precipitation of up to 87% of the peptide present. This precipitation is greatest in the presence of zinc (25 μ M) where the amount of A β recovered from the zinc incubation supernatant is nearly half of the amount recovered from the EDTA incubation supernatant (Fig. 3b). The effect of copper (25 μ M) upon kaolin-induced A β precipitation is similar to the effect of EDTA (Fig. 3b). The binding of A β to kaolin is not reversible to subsequent treatment with 10 mM EDTA, but can be eluted by 2 M NaOH.

To further test whether zinc induces irreversible precipitation of A β in the absence of kaolin, A β incubated with Zn²⁺ (200 μ M, 1-24 h, 20°C) was subjected to SDS Tris/Tricine gel electrophoresis. The monomeric species was the major band detected on Coomassie-stained gels and migrated

identically to unincubated A β , indicating that zinc does not induce covalent or SDS-resistant polymerization of A β .

The APP α -secretase site at Lys-16 (Esch *et al.*, *Science* 248:1122-1124 (1990); Sisodia *et al.*, *Science* 248:492-495 (1990)) in A β is within the obligatory zinc binding region. The ability of Zn²⁺ to protect A β from secretase-type cleavage was investigated using the serine-protease trypsin, whose activity is unaffected by zinc. Amino-terminal sequence on A β tryptic digestion products transferred to polyvinylidene difluoride membrane following SDS-polyacrylamide gel electrophoresis indicated two detectable fragments corresponding to residues 6-40 and 17-40 (Fig. 4a). The predicted tryptic cleavage product representing residues 29-40 did not appear on the blot and may not be retained by the polyvinylidene difluoride membrane during transfer and treatment. Digestion is inhibited by the presence of increasing concentrations of Zn²⁺. At 200 μ M, Zn²⁺ causes complete inhibition of A β hydrolysis; however, at this zinc level, tryptic activity is also slightly inhibited. Probing the blot with ⁶⁵Zn²⁺ confirmed the zinc binding identity of the peptide fragments and facilitated quantification of the hydrolysis of the zinc binding site (Fig. 4b). The rate of digestion of A β ₁₋₄₀ and the A β ₆₋₄₀ fragment is inhibited by the presence of zinc, whereas the digestion of the A β ₁₇₋₄₀ fragment is not inhibited by increasing zinc concentrations. Hence, only the peptides possessing the intact zinc binding domain of A β (residues 6-28), and therefore capable of binding Zn²⁺ (Fig. 4b), have their rates of digestion inhibited by zinc in this experiment. These data indicate that secretase-type cleavage of A β can be inhibited by Zn²⁺ binding to the A β substrate. The results of the preceding experiments can be summarized as follows.

Firstly, the data indicates that soluble A β ₁₋₄₀ possesses high and low affinity zinc binding sites. Secondly, the zinc binding site on A β maps to residues 6-28, with possibly conformational- and histidine-dependent properties. Thirdly, the affinity constants for zinc binding indicate that both binding associations are within physiological zinc concentrations. The binding of zinc may inhibit the action of α -secretase type cleavage of the peptide.

Furthermore, occupancy of the low affinity binding site may be associated with accelerated precipitation of A β by aluminum silicate (kaolin). Occupancy of the high affinity site appears to have little effect on A β precipitation and is very highly specific, although the data cannot exclude the possibility of specific binding sites for alternative metals elsewhere on A β . Finally, copper's strong conformational interaction (dimerization and fluorescence) with A β indicates that it may also directly interact with the peptide and may have a role in preventing A β precipitation onto aluminum silicate.

Extracellular zinc may modify the adhesiveness of APP to extracellular matrix elements (Bush *et al.*, *J. Biol. Chem.* 268:16109-16112 (1993)) and thus be an important factor in the physiology of the protein. Although the physiological function of APP remains unclear, the protein is thought to play a role in cell adhesiveness (Shivers *et al.*, *EMBO J.* 7:1365-1370 (1988)) and neurite outgrowth (Milward *et al.*, *Neuron* 9:129-137 (1992)). Physiological function of the A β -zinc interaction is also unclear, however, increased resistance of A β to proteolytic cleavage in the presence of zinc would increase the peptide's biological half-life, and the resulting increase in adhesiveness may also promote its binding to extracellular matrix elements. It has been reported recently that A β also promotes neurite outgrowth by complexing with laminin and fibronectin in the extracellular matrix (Koo *et al.*, *Proc. Natl. Acad. Sci. USA* 90:4748-4752 (1993)). Hence, both APP and A β may interact with the extracellular matrix to modulate cell adhesion. The possibility that zinc is a local environmental cofactor modulating this interaction merits further investigation.

APP is abundant in platelets and brain (Bush *et al.*, *J. Biol. Chem.* 265:15977-15983 (1990)) where zinc is also highly concentrated (Baker *et al.*, *Thromb. Haemostasis* 39:360-365 (1978); Frederickson, C.J., *Int. Rev. Neurobiol.* 31:145-328 (1989)). Although APP is concentrated in vesicles in both of these tissues (Bush *et al.*, *J. Biol. Chem.* 265:15977-15983 (1990); Schubert *et al.*, *Brain Res.* 563:184-194 (1991)), and zinc is actively taken up (Wolf *et al.*, *Neurosci. Lett.* 51:277-280 (1984)) and stored in synaptic vesicles in nerve terminals throughout the telencephalon (Perez-Clausell and

Danscher, *Brain Res.* 3371:91-98 (1985), the colocalization of APP with zinc in these vesicles has yet to be demonstrated. Vesicular zinc storage is thought to play a role in stabilizing functional molecules such as nerve growth factor (NGF) and insulin as insoluble intravesicular precipitates (Frederickson *et al.*, *J. Histochem. Cytochem.* 35:579-583 (1987)). Zinc may similarly play a role in stabilizing APP and A β .

The well characterized interaction between insulin and zinc has several striking parallels to the interaction of A β and zinc. Like A β , insulin exhibits histidine-dependent high-affinity ($K_a = 5 \mu\text{M}$) and low-affinity ($K_a = 140 \mu\text{M}$) zinc binding with stoichiometries of 1:1 (insulin:zinc) and 1:2, respectively (Goldman and Carpenter, *Biochemistry* 13:4566-4574 (1974)). Additionally, metal-free insulin exhibits a pH-dependent polymerization pattern consisting of monomer, dimer, tetramer, hexamer, and higher aggregation states, in dynamic equilibrium. At neutral pH, zinc and other divalent metal ions shift the equilibrium toward the higher aggregation states. At stoichiometric ratios of Zn^{2+} :insulin in excess of 0.33, the peptide precipitates (Fredericq, E., *Arch. Biochem. Biophys.* 65:218-228 (1956)), reminiscent of zinc's effects upon A β observed in the current studies.

A β chelates zinc with such high affinity that reports of its neurotoxic effects in neuronal cultures (Yankner *et al.*, *Science* 250:279-282 (1990); Koh *et al.*, *Brain Res.* 533:315-320 (1990)) might be explained by a disturbance of zinc homeostasis. A β accumulates most consistently in the hippocampus, where extreme fluctuations of zinc concentrations occur (0.15-300 μM) (Frederickson, C.J., *Int. Rev. Neurobiol.* 31:145-328 (1989)), *e.g.*, during synaptic transmission (Assaf and Chung, *Nature* 308:734-736 (1984); Howell *et al.*, *Nature* 308:736-738 (1984); Xie and Smart, *Nature* 349:521-524 (1991)). Choi and co-workers (Weiss *et al.*, *Nature* 338:212 (1989)) have proposed that this trans-synaptic movement of zinc may have a normal signaling function and may be involved in long term potentiation. The hippocampus is the region of the brain that both contains the highest zinc concentrations (Frederickson *et al.*, *Brain Res.* 273:335-339 (1983)) and is most severely and consistently affected by the pathological lesions of

Alzheimer's disease (Hyman *et al.*, *Ann. Neurol.* 20:472-481 (1986)). One of the prominent neurochemical deficits in Alzheimer's disease is cholinergic deafferentation of the hippocampus, which has been shown to raise the concentration of zinc in this region (Stewart *et al.*, *Brain Res.* 290:43-51 (1984)).

The rapid zinc-accelerated precipitation of A β by aluminum silicate (kaolin) is significant because of the candidacy of aluminum as a pathogenic agent in AD (Perl and Brody, *Science* 208:297-299 (1980)). Recent reports of Zn²⁺- and Al³⁺-induced sedimentation of A β (Mantyh *et al.*, *J. Neurochem.* 61:1171-1174 (1993)), and the nucleation of A β precipitation by aluminosilicate (Candy *et al.*, *Biochem. Soc. Trans.* 21:53S (Abstract) (1992)) also support these observations.

Evidence for altered zinc metabolism in AD includes decreased temporal lobe zinc levels (Wenstrup *et al.*, *Brain Res.* 533:125-131 (1990); Constantinidis, *Encephale* 16:231-239 (1990); Corrigan *et al.*, *Biometals* 6:149-154 (1993)), elevated (80%) cerebrospinal fluid levels (Hershey *et al.*, *Neurology* 33:1350-1353 (1983)), increased hepatic zinc with reduced zinc bound to metallothionein (Lui *et al.*, *J. Am. Geriatr. Soc.* 38:633-639 (1990)), a Zn²⁺-modulated abnormality of APP in AD plasma (Bush *et al.*, *Ann. Neurol.* 32:57-65 (1992)), an increase in extracellular Zn²⁺-metalloproteinase activities in AD hippocampus (Backstrom *et al.*, *J. Neurochem.* 58:983-992 (1992)), and decreased levels of astrocytic growth inhibitory factor, a metallothionein-like protein which chelates zinc (Uchida *et al.*, *Neuron* 7:337-347 (1991)). Collectively, these reports indicate that there may be an abnormality in the uptake or distribution of zinc in the AD brain causing high extracellular concentrations and low intracellular concentrations. Meanwhile, environmentally induced elevations of brain concentrations of both zinc (Duncan *et al.*, *J. Neurosci.* 12:1523-1537 (1992)) and aluminum (Garruto *et al.*, *Proc. Natl. Acad. Sci. USA* 81:1875-1879 (1984); Perl *et al.*, *Science* 217:1053-1055 (1982)) have been implicated in the pathogenesis of GALS/PDC complex, a disease also characterized by neurofibrillary tangles (Guiroy *et al.*, *Proc. Natl. Acad. Sci. USA* 84:2073-2077 (1987)).

Interestingly, a pervasive abnormality of zinc metabolism manifested by immunological and endocrine dysfunction has been described as a common complication of Down's syndrome (Franceschi *et al.*, *J. Ment. Defic. Res.* 32:169-181 (1988); Bjorksten *et al.*, *Acta. Pediatr. Scand.* 69:183-187 (1980)), a condition characterized by the invariable onset of presenile A β deposition and Alzheimer's disease (Rumble *et al.*, *N. Engl. J. Med.* 320:1446-1452 (1989)).

These results indicate that abnormally high zinc concentrations increase A β resistance to secretase-type cleavage and also accelerate A β precipitation onto aluminosilicates. Zinc-induced accumulation of A β in the neuropil may, in turn, invoke a glial inflammatory response, free radical attack, and oxidative cross-linking to form an, ultimately, "mature" amyloid. Collectively, these findings support the biochemical rationale for the chelation approach in the therapy of Alzheimer's disease (Crapper McLachlan *et al.*, *Lancet* 337:1304-1308 (1991)), since reduction of cerebral concentrations of both aluminum and zinc could potentially decelerate the precipitation of A β . The assay of the present invention is ideally suited for the preparation of a kit. Such a kit may comprise a carrier means being compartmentalized to receive in close confinement therein one or more container means, such as vials, tubes, and the like, each of said container means comprising one of the separate elements of the assay to be used in the method. For example, there may be provided a container means containing standard solutions of the A β peptide or lyophilized A β peptide and a container means containing a standard solution or varying amounts of a heavy metal cation capable of binding to the peptide comprising at least amino acids 6 to '28 of A β peptide, in any form, *i.e.*, in solution or dried, soluble or insoluble, in addition to further carrier means containing varying amounts and/or concentrations of reagents used in the present methods, *e.g.*, standard solutions or varying amounts of chelators of heavy metal cations in any form, in solution or dried. Standard solutions of A β peptide preferably have concentrations above about 10 μ M, more preferably from about 10 to about 25 μ M or if the peptide is provided in its lyophilized form, it is provided in an amount which can be solubilized to said

concentrations by adding an aqueous buffer or physiological solution. Standard solutions of heavy metal cations preferably have concentrations above 300 nM, more preferably about 25 μ M. The standard solutions of analytes may be used to prepare control and test reaction mixtures for comparison, according to the methods of the present invention for determining whether a compound inhibits formation of A β amyloid.

These studies show that A β binds zinc in a saturable and specific manner. Moreover, they demonstrate that physiological concentrations of Zn²⁺ increase the resistance of the peptide to proteolytic catabolism and promote A β precipitation by aluminosilicate. Based on these findings, it is possible that excessive zinc concentrations accelerate A β deposition in AD and related pathological conditions.

Further, the effects of physiological concentrations of zinc upon the stability of synthetic human A β_{1-40} in solution were studied, using the rat/mouse species of the peptide ("rat A β ") for comparison. Soluble A β_{1-40} is produced by rat neuronal tissue (C. Haass and D.J. Selkoe, personal communication), however, A β amyloid deposition is not a feature of aged rat brains (D.W. Vaughan and A. Peters, *J. Neuropathol. Exp. Neurol.* 40:472 (1981)). β -amyloidogenesis occurs in other aged mammals possessing the human A β sequence, which is strongly conserved in all reported animal species, except rat and mouse (E.M. Johnstone, M.O. Chaney, F.H. Norris, R. Pascual, S.P. Little, *Mol. Brain Res.* 10:299 (1991)). The rat/mouse A β substitutions (Arg \rightarrow Gly, Tyr \rightarrow Phe and His \rightarrow Arg at positions 5, 10 and 13, respectively [B.D. Shivers *et al.*, *EMBO J.* 7:1365 (1988)]) appear to cause a specific change in the peptide's physicochemical properties sufficient to confer upon the peptide its relative immunity to amyloid formation. Since zinc binding to human A β_{1-40} is histidine-mediated, the altered zinc binding properties of rat A β are entirely consistent with the proposed mechanism and binding site of the human peptide.

The binding affinity of zinc to rat A β_{1-40} was studied in a ⁶⁵Zn competitive assay system as described in Example 1 (FIG. 1), to measure the K_A of zinc binding to human A β_{1-40} . In contrast to human A β_{1-40} , the

Scatchard analysis of zinc binding to rat $A\beta_{1-40}$ reveals only one binding association ($K_A = 3.8 \mu\text{M}$), with 1:1 stoichiometry (FIG. 5).

It was observed that the recovery of human $A\beta_{1-40}$ in filtration chromatography is dramatically reduced in the presence of zinc, due, in part, to increased adhesiveness of $A\beta$. To determine whether the aggregation of human $A\beta_{1-40}$ is also enhanced in the presence of zinc, the peptide was incubated with various concentrations for 30 minutes with Zn^{2+} ($25 \mu\text{M}$) or EDTA and then filtered the solutions through 0.2μ filters. Zinc caused up to 80% of the available peptide to aggregate into $>0.2 \mu$ particles (FIG. 6A).

(Incubation of $A\beta_{1-40}$ solutions in the filter devices, without actual filtration, indicated that there was no non-specific loss of peptide to the plastic or membrane surfaces.) There appears to be a shallow negative log-linear relationship between human $A\beta$ peptide concentration and the proportion of filterable peptide in $25 \mu\text{M}$ Zn^{2+} , but even at the lowest concentration tested ($0.8 \mu\text{M}$), $>70\%$ of the human $A\beta_{1-40}$ solution aggregated. In contrast, the effect of Zn^{2+} on rat $A\beta_{1-40}$ was unremarkable, with no aggregation of a $0.8 \mu\text{M}$ peptide solution detected under the same conditions, and only 25% aggregation of a $4 \mu\text{M}$ solution. Meanwhile, in the presence of EDTA, human and rat $A\beta_{1-40}$ solutions behaved indistinguishably, with no detectable aggregation observed at $0.8 \mu\text{M}$, and $\approx 15\%$ aggregation at higher peptide concentrations.

Next, the formation of $>0.2 \mu$ $A\beta$ particles was titrated against increasing zinc concentrations (FIG. 6B), and a shallow response curve for human $A\beta_{1-40}$ ($1.6 \mu\text{M}$) was observed until the zinc concentration reached 300 nM, corresponding to the saturation of high-affinity binding. At zinc concentrations above 300 nM, corresponding to low-affinity binding, human $A\beta_{1-40}$ dramatically aggregates. In contrast, rat $A\beta_{1-40}$ remains stable in the presence of up to $10 \mu\text{M}$ zinc, and only at $25 \mu\text{M}$ zinc was aggregation observed.

To determine the effects of zinc on $A\beta_{1-40}$ at physiological peptide concentrations requires an assay more sensitive than spectroscopy. (Human $A\beta_{1-40}$ at $0.8 \mu\text{M}$ in buffer 1 corresponds to 0.090 absorbance units at 214 nm.

Aggregation studies of peptides at lower starting concentrations would involve readings at the limits of sensitivity). Thus, the effects of zinc on ^{125}I -human $\text{A}\beta_{1-40}$ used as a tracer in the presence of unlabeled peptide was characterized. Unlike its unlabeled precursor, ^{125}I - $\text{A}\beta_{1-40}$ (at $1.6\ \mu\text{M}$ total peptide) remained stable in the presence of increasing zinc concentrations, indicating that ^{125}I - $\text{A}\beta_{1-40}$ is not a suitable tracer (FIG. 6B). The tracer is iodinated on the tyrosine residue at position 10, which is a phenylalanine in the rat peptide. Thus, the tyrosine residue may be critical to the stability of the human peptide. These data may also explain why a recent report required relatively high concentrations of Zn^{2+} ($1\ \text{mM}$) to precipitate ^{125}I -human $\text{A}\beta_{1-40}$ in centrifugation studies (P.W. Mantyh *et al.*, *J. Neurochem.* 61:1171 (1993)). Extrapolating the curve in FIG. 6A to $0.6\ \text{nM}$ currently provides the best estimate of the effect of zinc upon physiological $\text{A}\beta$ concentrations (M. Shoji *et al.*, *Science* 258:126 (1992); P. Seubert *et al.*, *Nature* 359:325 (1992)), and indicates that 25% of the peptide would aggregate into $>0.2\ \mu$ particles under these conditions. The specific vulnerability of human $\text{A}\beta_{1-40}$ for Zn^{2+} is indicated by the observation that Zn^{2+} is the only one of several metal ions tested on an equimolar basis, including Al^{3+} , to induce significant aggregation of human $\text{A}\beta_{1-40}$ in this system (FIG. 6C).

Next, the kinetics of the assembly of zinc-induced human $\text{A}\beta_{1-40}$ aggregates (FIG. 6D) was investigated. (In order to achieve time point measurements of less than 1 minute, the procedure was modified so that samples were centrifuged at $2500g$, allowing the sample volume to be completely filtered in 40 seconds.) The data obtained indicate that following the addition of stock $\text{A}\beta_{1-40}$ in water ($15.9\ \mu\text{M}$, pH 5.6) to Zn^{2+} ($25\ \mu\text{M}$) in saline buffer (pH 7.4) there is a near-instantaneous aggregation of the peptide ($1.6\ \mu\text{M}$ final concentration) into filterable particles with two phases observed over two hours. The initial phase is rapid, with a half-maximal assembly rate of $\approx 0.4\ \mu\text{M}/\text{min}$. The steady state of the second phase is achieved within about 2 minutes, whereupon particle assembly proceeds at a rate of $3.2\ \text{nM}/\text{min}$ with no evidence of saturation within 2 hours. At this rate, the available peptide is exhausted within five hours of initiation. Although the

addition of EDTA buffer caused the near-instantaneous aggregation of 20% of the 1.6 μM $\text{A}\beta_{1-40}$ solution into $>0.2 \mu$ particles, no further particle assembly was observed over the time course of the experiment. In comparison, human $\text{A}\beta_{1-40}$ (20 μM in PBS, pH 7.4) has been reported to be stable for 10 days (J.T. Jarrett, E.P. Berger, P.T. Lansbury, *Biochemistry* 32:4693 (1993)), and seeding the solution with $\text{A}\beta_{1-42}$ (2 μM), the more amyloidogenic $\text{A}\beta$ species, induced aggregation of this solution which was half-maximal only after 4-5 days. Thus, the results presented here represent a major advance among attempts to induce amyloid formation *in vitro* using the wild-type form of the main species of secreted $\text{A}\beta$ ($\text{A}\beta_{1-40}$).

To estimate the size of the $\text{A}\beta$ aggregates formed in the presence of zinc, $\text{A}\beta_{1-40}$ (1.6 μM) was incubated with Zn^{2+} (25 μM) or EDTA and then passed through filters with various pore sizes (FIGs. 7a and 7b). Following incubation in EDTA, human $\text{A}\beta_{1-40}$ assembled into populations of heterogeneous particle sizes, $>0.1\mu$: 47%, $>0.22\mu$: 40%, $>0.65\mu$: 32%. The comparable proportions of filtered rat $\text{A}\beta_{1-40}$ particles were, $>0.1\mu$: 36%, $>0.22\mu$: 27%, $>0.65\mu$: 25%. Upon incubation with Zn^{2+} (25 μM), the proportion of $>0.65\mu$ rat peptide particles increased only slightly, however the proportion of $>0.65\mu$ human peptide particles dramatically increased, recruiting 82% of the available peptide. Interestingly, the proportions of $>0.1\mu$ and $>0.22\mu$ particles formed from the human $\text{A}\beta_{1-40}$ also increased by 50 and 55%, respectively, following incubation with Zn^{2+} , however, the same reaction induced only a 20% and 30% increase, respectively, in the amounts of these particles assembled from rat peptide. Remarkably, only 4% of the human $\text{A}\beta_{1-40}$ incubated with Zn^{2+} remained in solution following 0.1 μ filtration. Collectively, these data indicate that the human species of $\text{A}\beta_{1-40}$ differs from the rat species both in the extent and size of zinc-induced particle formation.

The stoichiometry of zinc:human $\text{A}\beta$ in these aggregates is at least 1:1 (FIG. 7c), but increases to 1.3:1 with the smaller (0.1 μ) pore size filters. Because the stoichiometries for high- and low- affinity $\text{Zn}:\text{A}\beta$ binding are $\approx 1:1$ and $\approx 2:1$ respectively, these data indicate that formation of $>0.65\mu$

A β aggregates is mediated by high-affinity zinc interaction, whereas low-affinity zinc interaction most likely contributes to the formation of smaller (<0.22 μ) aggregates. Interestingly, when the retained aggregates are washed with EDTA, only 22% of the peptide is recovered from >0.65 aggregates, although the complexed zinc (using ⁶⁵Zn as tracer) is completely recovered (FIG. 7d). This indicates that zinc-induced A β aggregation is largely irreversible by chelation. The amount of \leq 0.22 μ peptide resolubilized by EDTA treatment is 7% greater, which may reflect the increased contribution of low-affinity zinc binding to the smaller, chelation-reversible, A β particle formation.

Sedimentation of zinc-induced A β particles by centrifugation resulted in an abundant precipitate of human A β_{1-40} which stained with Congo Red (FIG. 8a) and manifested green birefringence under polarized light (FIG. 8b), meeting the criteria for tinctorial amyloid formation. However, following incubation with Zn²⁺ under the same conditions, the rat peptide formed significantly fewer and smaller particles, with minimal birefringence. No rat A β amyloid was induced by Zn²⁺ concentrations of less than 10 μ M, whereas, by tinctorial criteria, human A β amyloid was induced by Zn²⁺ concentrations as low as 3 μ M. In neither case was Congo Red-stained material detected following incubation with EDTA-containing buffer.

Taken together, these data indicate that soluble human A β_{1-40} has a dramatically greater propensity than rat A β_{1-40} to form amyloid in the presence of physiological zinc concentrations. The tinctorial amyloid aggregates are frequently as large as the amorphous amyloid plaque cores purified from AD brain tissue (C.L. Masters *et al.*, *Proc. Natl. Acad. Sci. USA* 82:4245 (1985)). Meanwhile, the small degree (10-20%) of >0.2 μ A β_{1-40} particle assembly observed following the incubation of A β_{1-40} with EDTA probably reflects the relatively slow aggregation which occurs in the presence of neutral pH (S. Tomski and R.M. Murphy, *Arch. Biochem. Biophys.* 294:630 (1992)) and NaCl (C. Hilbich, B. Kisters-Woike, J. Reed, C.L. Masters, K. Beyreuther, *J. Mol. Biol.* 218:149 (1991)). Hence, the specific vulnerability

of human A β to zinc-induced amyloid formation is a promising explanation for aspects of the pathology of AD and related pathological conditions.

The cerebral cortex, and especially the hippocampus, contains the highest concentrations of zinc in the body (C.J. Frederickson, M.A. Klitenick, W.I. Manton, J.B. Kirkpatrick, *Brain Res.* 273:335 (1983)), and is exposed to extreme fluctuations of extracellular zinc levels (0.15 to 300 μ M, C.J. Frederickson, *Int. Rev. Neurobiol.* 31:145 (1989)), e.g. during synaptic transmission (S.Y. Assaf and S.-H. Chung, *Nature* 308:734 (1984); G.A. Howell, M.G. Welch, C.J. Frederickson, *Nature* 308:736 (1984)). The cortical vasculature contains an intraluminal zinc concentration of 20 μ M (I.J.T. Davies, M. Musa, T.L. Dormandy, *J. Clin. Pathol.* 21:359 (1968)), but the perivascular interstitial zinc concentration is 0.15 μ M (C.J. Frederickson, *Int. Rev. Neurobiol.* 31:145 (1989)). Both sites of high zinc concentration gradients are severely and consistently affected by the pathological lesions of AD (B.T. Hyman, G.W. Van Hoesen, L.J. Kroner, A.R. Damasio, *Ann. Neurol.* 20:472 (1986); G.G. Glenner and C.W. Wong, *Biochem. Biophys. Res. Commun.* 120:885 (1984)). Interestingly, a prominent neurochemical deficit in AD is cholinergic deafferentation of the hippocampus, which raises the concentration of zinc in this region (G.R. Stewart, C.J. Frederickson, G.A. Howell, F.H. Gage, *Brain Res.* 290:43 (1984)). Additional evidence for altered cerebral zinc metabolism in AD include decreased temporal lobe zinc levels (D. Wenstrup, W.D. Ehmann, W.R. Markesbery, *Brain Res.* 533:125 (1990); J. Constantinidis, *Encephale* 16:231 (1990); F.M. Corrigan, G.P. Reynolds, N.I. Ward, *Biometals* 6:149 (1993)), elevated (80%) CSF levels (C.O. Hershey *et al.*, *Neurology* 33:1350 (1983)), an increase in extracellular Zn²⁺-metalloproteinase activities in AD hippocampus (J.R. Backstrom, C.A. Miller, Z.A. Tökés, *J. Neurochem.* 58:983 (1992)), and decreased levels of astrocytic growth-inhibitory factor, a metallothionein-like protein which chelates zinc (Y. Uchida, K. Takio, K. Titani, Y. Ihara, M. Tomonaga, *Neuron* 7:337 (1991)). Recently, a clinical study assayed the effects of oral zinc supplementation (6.7-fold the recommended daily allowance, a dose commonly found in nutritional

supplements) upon cognition and plasma APP levels in AD subjects and age-matched controls. Five sequentially-studied AD subjects each experienced an acute decline in cognition within forty-eight hours of ingesting the zinc dose. Under the same conditions, age-matched control subjects remained unaffected by the dose. Among the abnormal changes of neuropsychological measurements taken of the AD group was a 31% drop in Mini-Mental State Examination (M.F. Folstein, S.E. Folstein, P.R. McHugh, *J. Psychiatr. Res.* 12:189 (1975)) scores, after four days of zinc supplementation. This represented a deterioration which, in the ordinary course of the disease, would only be expected after two to four years (Galasko *et al.*, *JAGS* 39:932 (1991)). Plasma APP levels also rose significantly in response to zinc in both the AD and the control groups. All changes were rapidly reversible following cessation of the four day supplementation. Collectively, these reports indicate that there may be an abnormality in the uptake or distribution of zinc in the AD brain. Pervasive abnormalities of zinc metabolism, and premature AD pathology, are also common clinical complications of Down's syndrome (C. Franceschi *et al.*, *J. Ment. Defic. Res.* 32:169 (1988); B. Rumble *et al.*, *N. Engl. J. Med.* 320:1446 (1989)).

The data presented here indicate that stability in the presence of physiological concentrations of zinc clearly differentiates the propensity of human and rat $A\beta_{1-40}$ peptide species to form amyloid. The rapid induction of tinctorial human $A\beta$ amyloid, under physiologically relevant conditions, at peptide concentrations more than an order of magnitude lower than the lowest levels achieved previously for $A\beta_{1-40}$ aggregation, and within two minutes of incubation, establishes a novel assay system for the study of $A\beta$ amyloidosis. More importantly, these findings can have profound implications for the potential role of zinc in Alzheimer-associated neuropathogenesis.

The following examples are provided by way of illustration to further describe certain preferred embodiments of the invention, and are not intended to be limiting of the present invention, unless specified.

Examples

Experimental Procedures

Unless otherwise indicated, the following experimental procedures, materials, and reagents were used in the present invention:

5 **Reagents**--Precautions taken to avoid zinc contamination included using analytical-grade reagents, electrophoresis-grade Tris-HCl (Bio-Rad), and highly deionized water. $A\beta_{1-17}$ was synthesized by the Biopolymers Laboratory, MIT. $A\beta_{40-1}$ (reverse peptide) was purchased from Bachem (Torrance, CA). Other reagents were from Sigma. $A\beta_{1-40}$ and $A\beta_{1-28}$ results were replicated with peptides from Bachem and Sigma. $A\beta_{1-40}$ results were also replicable with peptide synthesized by W. M. Keck Foundation Biotechnology Resource Laboratory, Yale University. ^{65}Zn was purchased from Amersham Corp.

15 **$^{65}\text{Zn}^{2+}$ Binding Studies**--Dissolved peptides (1.2 nMol, unless otherwise stated) were dot-blotted onto polyvinylidene difluoride membrane (0.2- μm pore size; Pierce Chemical Co.), washed twice with chelating buffer (200 μl x 100 mM NaCl, 20 mM Tris-HCl, 1 mM EDTA, pH 7.4), then five times with blocking buffer (200 μl x 100 mM NaCl, 20 mM Tris-HCl, 1 mM MnCl_2 , pH 7.4), and then incubated (60 min, 20°C) with ^{65}Zn (unless otherwise stated 20 130,000 cpm, 74 mM $^{65}\text{ZnCl}_2$ in 200 μl of blocking buffer \pm competing metal ion chloride). The dot-blot was then washed with blocking buffer (5 x 200 μl), the dot excised, placed in a test tube, and assayed by γ -counting (11% efficiency). The equilibration volume for stoichiometry estimates was regarded as 6 x 200 μl . The 214 nm UV absorbance of the unbound flow-through was assayed to determine the total amount of peptide remaining bound 25 onto the membrane. Peptide stock concentrations were confirmed by amino acid analysis. To alter the pH, the ^{65}Zn incubation was carried out in the presence of 100 mM buffer: MOPS (pH 6.5-7.0), MES (pH 5.0-6.0), acetate

(pH 3.5-4.5). The dot-blot apparatus was washed with detergent and EDTA (50 mM) then rinsed and siliconized between use.

A β Chromatography--A β (55 μ g) was incubated with metal salt solution or EDTA in siliconized 1.5-ml plastic reaction vessels in 100 mM NaCl, 20 mM Tris-HCl, pH 7.4 ("TBS," 100 μ l, 1 h, 37°C). A β was stored in aliquots of 0.52 mg/ml in water at -20°C, then kept at 4°C when thawed. Reagents were mixed without vortex mixing. The incubated A β was directly applied to a G50 SF (Pharmacia, Uppsala, Sweden) column (Bio-Rad Econo-Column, 30 x 0.7 cm) pre-equilibrated with metal salt solution or EDTA (50 μ M) in TBS at 20°C and eluted at 8 ml/h (Wiz peristaltic pump, Isco, Lincoln, NE). Absorbance was measured at 254 and 214 nm (Type 6 optical unit, Isco). The amount of A β eluting at various peaks was estimated from the area under the curve. This was possible because the relationship of UV absorbance was determined to be linear over the range of A β dilutions used in these studies, indicating that absorbance is proportional to the amount of peptide present despite polymerization state (see below). The maximum recovery of A β occurs in the presence of EDTA. Because the sample eluted in a volume of approximately 15 ml, the average concentration of the peptide on the column was 0.8 μ M.

To study the effects of protein blocking upon adsorption of A β to the chromatography column, a Sephadex G50 SF column which had been characterized previously for A β behavior was eluted with 3% bovine serum albumin (BSA) in TBS (50 ml) and equilibrated with non-BSA-containing buffer, subsequent to repeating the A β experiments.

Spectroscopic Assay--Measurements were performed on a Hewlett-Packard 8452A diode array spectrophotometer using a 1-cm path length quartz cuvette. Concentration *versus* absorbance curves were performed at 214 nm, 254 nm, 280 nm, and full spectrum. 214 nm readings were 50-fold more sensitive in detecting the peptide than 254 nm readings, whereas the 280 nm readings of low micromolar A β solutions were below sensitivity limits and

hence could not be used in these studies. The standard curves generated were linear at concentrations below 0.1 mg/ml. In addition, the effects of Cu^{2+} , Zn^{2+} , EDTA, and TBS upon absorbance were examined. At concentrations below 0.1 mg/ml, adjusting the peptide in water to TBS caused $\approx 15\%$ quenching. Cu^{2+} -, Zn^{2+} -, and EDTA-containing $\text{A}\beta$ solutions were studied for artifactual absorbance over the linear range of the 214 nm absorbance curve. 1 mM EDTA caused 60% quenching, hence 50 μM EDTA was employed, contributing a similar degree of quenching to that observed with Cu^{2+} and Zn^{2+} .

$\text{A}\beta$ Binding to Kaolin (Aluminum Silicate)--Kaolin suspension was prepared in high performance liquid chromatography water (Fisher), defined, and adjusted to 50% (v/v). $\text{A}\beta$ (40 μg) was incubated in siliconized reaction vessels with either kaolin or Sephadex G50 SF (10 μl x 50% (v/v)) in Cu^{2+} , Zn^{2+} , or EDTA (100 μl in TBS, 5 min, room temperature). The suspension was then pelleted (1500 x g, 3 min) and the supernatant removed and diluted 20-fold with water to bring the UV absorbance readings into the linear range. Samples were assayed at 214 nm before and after incubation with kaolin or Sephadex.

Tryptic Digestion of $\text{A}\beta$ - $\text{A}\beta_{1-40}$ (13.9 μg) was incubated with Zn^{2+} (12 μl in blocking buffer, 1 h, 37°C) and then digested with trypsin (12 ng, 3 h, 37°C). The reaction was stopped by adding SDS sample buffer containing phenylmethylsulfonyl fluoride (1 mM), boiling the samples (5 min), and applying the samples to Tris/Tricine gel electrophoresis and transfer. The blot was washed with EDTA, Coomassie-stained, incubated with $^{65}\text{Zn}^{2+}$, individual bands were excised, assayed for $^{65}\text{Zn}^{2+}$ binding, and N-terminal sequenced to confirm the identity of the digestion products. The effects of Zn^{2+} (up to 100 μM in TBS) on the activity of trypsin, itself, were assayed by assay of Z-Arg-amido-4-methylcoumarin (Sigma) fluorescent cleavage product and determined to be negligible. It was found that 200 μM Zn^{2+} , however, inhibited tryptic activity by 12%.

Zinc- or Copper-treated microwell plate

Any standard microtitre plate, for example a Costar catalog no. 9017, can be used for making the heavy metal cation substrate which can trap A β protein. The plate is coated with a solvated nitrilotriacetic acid. Next, the divalent metal ion of choice, for example, zinc or copper metal cation, is added, which complexes to the surface of the plate. A preferred metal cation microtiter plate is available from Xenopore, Saddle Brook, New Jersey (catalog number for zinc plates: ZCP00100, catalog number for copper plates: CCP00100). It is preferred that like the zinc and copper plates made by Xenopore, there be at least two free coordination sites available for binding to A β protein. In this way, the A β protein can competitively attach to and stay bound to the substrate via the heavy metal cation.

Chelating-Sepharose Chromatography

The chelating-Sepharose resin (250 μ l) was poured into a disposable polystyrene column (Pierce, 29920) and packed between two porous polyethylene discs. In the following steps solutions were allowed to drain through the gel bed by gravity. The gel was first pre-equilibrated with 5 ml of equilibration buffer (MES 50 mM, pH 5.0 and NaCl 500 mM). The sample (10-15 ml) was then loaded on to the column. The gel was washed with 5 ml of equilibration buffer before bound protein was recovered by applying 1 ml of elution buffer to the gel (EDTA 50 mM, MES 50 mM, pH 5.0 and NaCl 500 mM) and collecting the eluate.

Example 1: Analyses of $^{65}\text{Zn}^{2+}$ binding to A β

Aliquots of A β were incubated (60 min) with $^{65}\text{Zn}^{2+}$ in the presence of varying concentrations of unlabeled Zn^{2+} (0.01-50 μ M total). The proportion of $^{65}\text{Zn}^{2+}$ binding to immobilized peptide (1.0 nmol) described two binding curves as shown in Figure 1a (Scatchard plot). Values shown are means \pm S.D., $n \geq 3$. The high-affinity binding curve has been corrected by subtracting the low-affinity component, and the low-affinity curve has had the high-affinity component subtracted. (FIG. 1b) depicts specificity of the Zn^{2+}

binding site for various metals. A β was incubated (60 min) with $^{65}\text{Zn}^{2+}$ (157 nM, 138,000 cpm) and competing unlabeled metal ions (50 μM total). (FIG. 1c) depicts $^{65}\text{Zn}^{2+}$ (74 nM, 104,000 cpm) binding to negative (aprotinin, insulin α -chain, reverse peptide 40-1) and positive (bovine serum albumin (BSA)) control proteins and A β fragments (identified by their residue numbers within the A β sequence, *gln11* refers to A β_{1-28} where residue 11 is glutamine). Percent binding of total counts $^{65}\text{Zn}^{2+}$ /min added is corrected for the amounts (in nanomoles) of peptides adhering to the membrane. (FIG. 1d) depicts as for 1a, except with A β_{1-28} peptide substituting for A β_{1-40} . 157 nM ^{65}Zn (138,000 cpm) is used in this experiment to probe immobilized peptide (1.6 nmol). (FIG. 1e) depicts pH dependence of $^{65}\text{Zn}^{2+}$ binding to A β_{1-40} .

Example 2: Effect of Zn^{2+} and other metals on A β polymerization using G50 gel filtration chromatography

Results shown are indicative of $n \geq 3$ experiments where 55 μg of A β is applied to the column and eluted in 15 ml, monitored by 254 nm absorbance. (FIG. 2a) depicts chromatogram of A β in the presence of EDTA, 50 μM , Zn^{2+} , 0.4 μM ; Zn^{2+} , 25 μM ; and Cu^{2+} , 25 μM . The elution points of molecular mass standards and relative assignments of A β peak elutions are indicated. Mass standards were blue dextran (2×10^6 kDa, V_0 = void volume), BSA (66 kDa), carbonic anhydrase (29 kDa), cytochrome *c* (12.4 kDa), and aprotinin (6.5 kDa). The mass of A β is 4.3 kDa. (FIG. 2b) depicts relative amounts (estimated from areas under the curve) of soluble A β eluted as monomer, dimer, or polymer in the presence of various metal ions (25 μM), varying concentrations of Zn^{2+} or Cu^{2+} (the likelihood of Tris chelation is indicated by upper limit estimates), and EDTA. Data for experiments performed in the presence of copper were taken from 214 nm readings and corrected for comparison. (FIG. 2c) depicts effects of pre-blocking the chromatography column with BSA upon the recovery of A β species in the presence of zinc (25 μM), copper (25 μM), or chelator.

Example 3: *A β binding to kaolin (aluminum silicate): effects of zinc (25 μ M), copper (25 μ M), and EDTA (50 μ M)*

(FIG. 3a) depicts concentration (by 214 nm absorbance) of A β remaining in supernatant after incubation with 10 mg of G50 Sephadex. (FIG. 3b) depicts concentration (by 214 nm absorbance) of A β remaining in supernatant after incubation with 10 mg of kaolin, expressed as percent of the starting absorbance.

Example 4: *Effect of Zn²⁺ upon A β resistance to tryptic digestion*

(FIG. 4a) depicts a blot of tryptic digests of A β (13.9 μ g) after incubation with increasing concentrations of zinc (lane labels, in micromolar), stained by Coomassie Blue. Digestion products of 3.6 kDa (A β_{6-40}), and 2.1 kDa (A β_{17-40}), as well as undigested A β_{1-40} (4.3 kDa), are indicated on the *left*. The migration of the low molecular size markers (*STD*) are indicated (in kilodaltons) on the *right*. (FIG. 4b) depicts ⁶⁵Zn²⁺ binding to A β tryptic digestion products. The blot in 4a was incubated with ⁶⁵Zn²⁺, the visible bands excised, and the bound counts for each band determined. These data are typical of *n* = 3 replicated experiments.

Example 5: *Scatchard analysis of ⁶⁵Zn binding to rat A β_{1-40}*

Dissolved peptides (1.2 nmol) were dot-blotted onto 0.20 μ PVDF membrane (Pierce) and competition analysis performed as described in Example 1 to measure the K_A of zinc binding to human A β_{1-40} (Figure 1).

In the present invention, rat A β_{1-40} and human A β_{1-40} were synthesized by solid-phase Fmoc chemistry. Purification by reverse-phase HPLC and amino acid sequencing confirmed the synthesis. The tabulated results are presented in Figure 5. The regression line indicates a K_A of 3.8 μ M. Stoichiometry of binding is 1:1. Although the data points for the Scatchard curve are slightly suggestive of a biphasic curve, a biphasic iteration yields association constants of 2 and 9 μ M, which does not justify an interpretation of physiologically separate binding sites.

Example 6: Effect of zinc upon human, ^{125}I -human and rat $\text{A}\beta_{1-40}$ aggregation into $>0.2\ \mu$ particles

Stock human and rat $\text{A}\beta_{1-40}$ peptide solutions ($16\ \mu\text{M}$) in water were prefiltered (Spin-X, Costar, $0.2\ \mu$ cellulose acetate, 700g), brought to 100 mM NaCl, 20 mM Tris-HCl, pH 7.4 (buffer 1) \pm EDTA ($50\ \mu\text{M}$) or metal chloride salts, incubated (30 minutes, 37°C) and then filtered again (700g, 4 minutes). The fraction of the $\text{A}\beta_{1-40}$ in the filtrate was calculated by the ratio of the filtrate OD_{214} (the response of the OD_{214} , titrated against human and rat $\text{A}\beta_{1-40}$ concentrations (up to $20\ \mu\text{M}$ in the buffers used in these experiments), was determined to be linear relative to the OD_{214} of the unfiltered sample. The results are tabulated in Figure 6. All data points are in triplicate, unless indicated. (FIG. 6a) Proportions of $\text{A}\beta_{1-40}$, incubated $\pm \text{Zn}^{2+}$ ($25\ \mu\text{M}$) or EDTA ($50\ \mu\text{M}$) and then filtered through $0.2\ \mu$, titrated against peptide concentration. (FIG. 6b) Proportion of $\text{A}\beta_{1-40}$ ($1.6\ \mu\text{M}$) filtered through $0.2\ \mu$, titrated against Zn^{2+} concentration. ^{125}I -human $\text{A}\beta_{1-40}$ (^{125}I -human $\text{A}\beta_{1-40}$ was prepared according to the method in J.E. Maggio, *PNAS USA* 89:5462-5466 (1992) (15,000 CPM, the kind gift of Dr. John Maggio, Harvard Medical School) was added to unlabeled $\text{A}\beta_{1-40}$ ($1.6\ \mu\text{M}$) as a tracer, incubated and filtered as described above. The CPM in the filtrate and retained on the excised filter were measured by a γ -counter. (FIG. 6c) Proportion of $\text{A}\beta_{1-40}$ ($1.6\ \mu\text{M}$) filtered through $0.2\ \mu$ following incubation with various metal ions ($3\ \mu\text{M}$). The atomic number of the metal species is indicated. (FIG. 6d) Effects of Zn^{2+} ($25\ \mu\text{M}$) or EDTA ($50\ \mu\text{M}$) upon kinetics of human $\text{A}\beta_{1-40}$ aggregation measured by $0.2\ \mu$ filtration. Data points are in duplicate.

Example 7: Size estimation of zinc-induced $\text{A}\beta$ aggregates

(FIGs. 7a and 7b) Proportion of $\text{A}\beta_{1-40}$ ($1.6\ \mu\text{M}$ in buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4)), was incubated $\pm \text{Zn}^{2+}$ ($25\ \mu\text{M}$) or EDTA ($50\ \mu\text{M}$) and was then filtered through filters of indicated pore sizes (Durapore filters (Ultrafree-MC, Millipore) were used for this study, hence there is a slight discrepancy between the values obtained with the $0.22\ \mu$ filters in this study compared to values obtained in FIG. 2 using $0.2\ \mu$ Costar filters).

(FIG. 7c) $^{65}\text{ZnCl}_2$ (130,000 CPM, 74 nM) was used as a tracer of the assembly of the zinc-induced aggregates of human $\text{A}\beta_{1-40}$ produced in FIG. 3A. By determining the amounts of $\text{A}\beta_{1-40}$ and ^{65}Zn in the filtrate, the quantities retarded by the filters could be determined, and the stoichiometry of the zinc: $\text{A}\beta$ assemblies estimated. (FIG. 7d) Following this procedure, the filters, retaining Zn: $\text{A}\beta$ assemblies, were washed with buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4) + EDTA (50 μM x 300 μl , 700g, 4 minutes). The amounts of zinc-precipitated $\text{A}\beta_{1-40}$ resolubilized in the filtrate fraction were determined by OD_{214} , and expressed as a percentage of the amount originally retained by the respective filters. ^{65}Zn released into the filtrate was measured by γ -counting.

Example 8: Zinc-induced tinctorial amyloid formation

(FIG. 8a) depicts Zinc-induced human $\text{A}\beta_{1-40}$ precipitate stained with Congo Red. The particle diameter is 40 μ . $\text{A}\beta_{1-40}$ (200 μl x 25 μM in buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4)) was incubated (30 minutes, 37°C) in the presence of 25 μM Zn^{2+} . The mixture was then centrifuged (16,000g x 15 minutes), the pellet washed in buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4) + EDTA (50 μM), pelleted again and resuspended in Congo Red (1% in 50% ethanol, 5 minutes). Unbound dye was removed, the pellet washed with buffer 1 (100 mM NaCl, 20 mM Tris-HCl, pH 7.4) and mounted for microscopy. (FIG. 8b) The same aggregate visualized under polarized light, manifesting green birefringence. The experiment was repeated with EDTA (50 μM) substituted for Zn^{2+} and yielded no visible material.

Example 9: Effect of zinc and copper upon human, ^{125}I -human and rat $\text{A}\beta_{1-40}$ aggregation into >0.2 μ particles

Stock human and rat $\text{A}\beta_{1-40}$ peptide solutions (16 μM) in water were pre-filtered (Spin-X, Costar, 0.2 μ cellulose acetate, 700g), brought to 100 mM NaCl, 20 mM Tris-HCl, pH 7.4 (buffer 1) \pm EDTA (50 μM) or metal chloride salts, incubated (30 minutes, 37°C) and then filtered again (700g, 4 minutes). The fraction of the $\text{A}\beta_{1-40}$ in the filtrate was calculated by the ratio

of the filtrate OD₂₁₄ (the response of the OD₂₁₄, titrated against human and rat A β ₁₋₄₀ concentrations (up to 20 μ M in the buffers used in these experiments), was determined to be linear) relative to the OD₂₁₄ of the unfiltered sample. All data points are in triplicate, unless indicated. (FIG. 9) A graph showing the proportions of A β ₁₋₄₀, incubated \pm Zn²⁺ (25 μ M) or Cu²⁺ or EDTA (50 μ M) and then filtered through 0.2 μ , titrated against peptide concentration.

Example 10: Effect of zinc upon A β produced in cell culture

A cell culture, preferably mammalian cell culture, expressing, preferably overexpressing, human APP is established according to well-known methods in the art, e.g. N. Suzuki *et al.*, *Science* 264:1336-1340 (1994); X-D Cai *et al.*, *Science* 259:514-516 (1993); F.S. Esch *et al.*, *Science* 248:1122-1124 (1990). Next, zinc is added to the culture medium to final concentration from about 200 nM to about 5 μ M. Then the cell cultures, containing zinc, are incubated from about 15 minutes to as long as they can survive in the culture. Preferably, the cells are incubated for 3 to 4 days. While fresh media may be added to the cultures, no spent medium should be taken out since it contains amyloid or zinc-induced A β aggregates.

The media which can be used are isotonic or physiological media, at physiological pH (about 7.4). Preferably Tyrode's buffer is used with calcium, magnesium, and potassium, as well as glucose. Any medium used must be devoid of cysteine, glutamate, aspartate, and histidine since these amino acids chelate zinc. Basically, any isotonic buffer or physiological medium which minimizes constituents which chelate zinc may be used. For example, Krebs Mammalian Ringer Solutions, in *Data for Biochemical Research*, 3d Edition by Dawson *et al.*, Oxford Science Publications, pp.446 (N.Y. 1986), and page 447 for Balanced Salt Solutions, provide recipes for making various useful media. The constituents that should be left out are serum and the four amino acids mentioned above.

The cell culture should be incubated at about 37 degrees centigrade with air or O₂/CO₂ (the maximum concentration of CO₂ is 5%).

Next, the cells and the medium are harvested together. A detergent such as Triton (at concentrations of about 1-2% v:v) is added and the mixture is incubated for about 3 minutes to overnight. Preferably, however, it is incubated for about 1 to 2 hours.

5 After incubation, the cell debris as well as amyloid and zinc-induced A β aggregates are pelleted by centrifugation. The pellet is suspended in pepsin (about 2%) or in any other peptidase, and it is incubated from about 1 hour to overnight to allow digestion of the cell debris.

10 Again, it is pelleted, washed with PBS or any other appropriate salt solution, stained with Congo Red, washed again, pelleted to remove any unbound Congo Red, and resuspended in aqueous solution. At this point, a sample can be visually inspected under a microscope. Further, it can be quantitated using a grid.

15 *Example 11: Assay for predicting the effectiveness of candidate reagents in cell culture*

The assay is set up in duplicate as described in Example 10. However, a candidate reagent is added to one of the two cell cultures and EDTA is added to the other cell culture. After the final step in Example 10, the amount of amyloid and zinc-induced A β aggregates are compared under the microscope. The probability and level of effectiveness of the candidate reagent is assessed based on the degree decrease in formation of amyloid and zinc-induced A β aggregates in the cell culture.

20 *Example 12: Rapid assay for detection of A β amyloid formation in biological fluid*

25 Cerebrospinal fluid (CSF) is obtained from a healthy human subject (control) and a human patient suspected of amyloidosis. Both samples of CSF are titrated by serial dilutions, e.g., neat, 1:2, 1:4, 1:6, ...; dilutions may be made up to 1:10,000.

To each of the samples, an equal amount of A β peptide in water is added to the final concentration of above about 10 μ M, preferably about 10 to about 25 μ M.

5 . Next, a solution which contains a heavy metal cation capable of binding to a peptide comprising at least amino acids 6 to 28 of A β , preferably Zn²⁺, plus NaCl and a buffer, *e.g.*, Tris at pH 7.4, is added to the final heavy metal cation, *e.g.*, Zn²⁺, to a final concentration of about above 300 nM, preferably 25 μ M.

10 Then, the samples are centrifuged to form pellets. Pellets are stained with an amyloid-staining dye, *e.g.*, Congo Red, and observed under a microscope, thereby comparing levels of A β amyloid in the control versus the sample from the patient with amyloidosis. If quantification of amyloid is desired, a grid can be used.

15 ***Example 13: Rapid assay for detection of A β amyloid formation in biological fluid using ³H-A β***

The assay is set up as explained in Example 12, except that the A β peptide added is labelled beforehand by tritium. Moreover, after centrifugation, the pellets are counted in a scintillation counter.

20 The preferred method of detecting the amyloid, however, is by using filtration techniques as described above instead of centrifugation. After the samples are passed through a filter, the filters are added to scintillation fluid and the counts are determined

25 Comparing the CPM from control samples with samples of the suspected amyloidosis patient, it can be determined whether the patient is in fact afflicted with amyloidosis. That is, an elevated CPM count in the patient samples compared to the control samples is indicative of amyloidosis.

Example 14: ELISA for detection and/or quantification of A β peptides

30 A β -specific antibody of the enzyme-antibody conjugate binds to A β peptide bound to the heavy metal cation which is bound to the microtiter well surface. The conjugated enzyme cleaves a substrate to generate a colored

reaction product that can be detected spectrophotometrically. The absorbance of the colored solution in individual microtiter wells is proportional to the amount of A β peptide.

This assay is optimized for detection and quantitation of A β peptide in neat body fluids or in a partially purified or purified A β peptide preparation.

Pretreatment of Samples Before ELISA

The body fluid or sample of partially purified A β may be treated prior to transfer to the 96-well plate to increase the efficiency of A β absorption to the solid-phase support. Treatments can include, but are not restricted to: pre-incubation with methylating agents such as N-methyl maleimide (1-10 mM for 1-2 hr) that disrupt protein metal binding sites involving a cysteine residue (the A β peptide does not contain a cysteine residue); the addition of soluble metal salts such as soluble MgCl₂ (0.5-5 mM) that block non-specific metal binding sites on proteins; the addition of compounds such as CuCl₂ (0.2-2 mM) which can change the polymerization state of A β ; and the addition of buffers to acidify the solution.

Materials

A β peptide (purified or partially purified) or neat body fluid
and controls (synthetic peptide standard)

Coating buffer (Tris 20 mM, pH 7.4, 150 mM NaCl)

Diluting buffer (Tris 20 mM, pH 7.4, 150 mM NaCl)

Blocking buffer (2% gelatine, Tris 20 mM, pH 8.0, 150 mM NaCl)

Wash buffer (Tris 20 mM, pH 8.0, 150 mM NaCl)

Normal saline (150 mM NaCl)

10 mM diethanolamine, pH 9.5, containing 0.5 mM MgCl₂

Urease-, HRPO-, or alkaline phosphatase-A β peptide conjugate

(prepared as described in UNIT 11.1 of *Current Protocols in Molecular Biology*, Vol. 2, Ausubel *et al.*, editors, (Greene Publishing Associates and Wiley-Interscience, publishers), New York.

Urease substrate solution (Allelix #1001 100), peroxidase substrate solution (Kirkegaard and Perry #50-62-00), or alkaline phosphatase substrate solution

Zinc (Xenopore ZCP 00100) or Copper (Xenopore CCP 00100)

5 96-well microtiter plates (or other heavy metal cation bound plates as described in Materials and Methods)

Multichannel pipet

Adhesive covers or tape for covering microtiter plates

Microtiter plate spectrophotometer with 590-nm and/or 405-run filters

10 1. Dissolve purified or partially purified A β peptide and controls in coating buffer at about 0.2-2.0 μ g/ml.

Depending on the affinity of the antibody for the A β peptide, it may be necessary to increase or decrease the amount of A β peptide or neat body fluid in coating buffer.

15 *For specificity testing, include closely related control antigens which the antibody should not recognize.*

2. Fill columns 2 through 12 of a 96-well microtiter plate with 0.1 ml coating buffer.

A 96-well plate is divided into 12 columns (labeled 1-12) and 8 rows (labeled A-H).

20 3. Starting in column 1 of a 96-well microtiter plate, serially dilute A β peptide in coating buffer. Place 0.2 ml of A β peptide solution in each well in column 1. Remove 0.1 ml from each well with a multichannel pipet and transfer to each well in column 2, which contains 0.1 ml of coating buffer. Pipet material in column 2 five times up and down. Remove 0.1 ml from each well in column 2 and transfer to column 3. Repeat this procedure through column 11. Remove 0.1 ml from column 11 and discard. Leave column 12 blank. Prepare two identical plates for duplicate assays. For controls prepare plates as per steps 2 and 3, using control material in place of A β solution. An example of a control material is a coating buffer without A β peptide.

25

30

This will give a range of dilutions in each of 8 rows (A to H) from 1:1 through 1:1,024 [i.e., column number (dilution); 1 (1:1), 2 (1:2), 3 (1:4), 4 (1:8), 5 (1:16), 6 (1:32), 7 (1:64), 8 (1:128), 9 (1:256), 10 (1:512), and 11 (1:1,024)].

5 4. Cover the plates with adhesive covers or tape and incubate for 2 hours at 37°C.

5. Remove A β peptide solution by shaking into a sink and fill all wells with 0.3 ml blocking buffer. Incubate for 2 h at 37°C.

10 *HRPO is inactivated by sodium azide. Do not use buffers containing sodium azide with HRPO-antibody conjugates. Filter sterilize buffers used routinely (i.e., diluting buffer) and store at 4°C.*

15 6. Remove blocking buffer by shaking into a sink and add 0.3 ml of washing buffer. Empty wells and refill with washing buffer. Repeat one more time.

7. Remove washing buffer by shaking into a sink and then fill rows B to H with 0.1 ml diluting buffer.

20 8. Add 0.2 ml of enzyme-antibody conjugate diluted in diluting buffer to row A of each plate. Recommended starting dilution of conjugate is 1:100. Serially dilute conjugate from row A to row H by transferring 0.1 ml to the well in the next row, as described in step 3. Final volume of conjugate in each well should be 0.1 ml.

25 *This will give a range of dilution from 1:100 through 1:12,800 [row (dilution): A (1:100), B (1:200), C (1:400), D (1:800), E (1:1,600), F (1:3,200), G (1:6,400), and H (1:12,800)].*

9. Cover the plates with adhesive covers or tape and incubate for a set length of time at a controlled temperature.

30 *Time and temperature of incubation are determined empirically. Generally, 30 to 90 min at 37°C is sufficient. Longer times of incubation may increase sensitivity, but nonspecific binding may also increase. An example is the monoclonal mouse antibody 6E10. For example, the mouse mAb 6E10 has an optimal*

incubation of 2 h at 37°C or overnight at room temperature (18-20°C).

10. Shake out the plates into a sink. Wash plates with wash buffer twice (0.3 ml each time) for urease- or alkaline phosphatase-antibody conjugates and four times for HRPO-antibody conjugates by filling well and shaking out the wash buffer into a sink. If an urease-antibody conjugate was used, rinse plates an additional three times with normal saline. If an alkaline phosphatase-antibody conjugate was used, rinse plates twice with 10 mM diethanolamine, pH 9.5, containing 0.5 mM MgCl_2 . Pat plates dry by inverting on a paper towel.
11. Add 0.2 ml of either urease, peroxidase, or alkaline phosphatase substrate solution, depending on the enzyme-antibody conjugate used. For example, a high sensitivity substrate for HRPO is a TMB solution (Pierce catalog no. 34024) and that is measured at 450 nm. Appropriate absorbances include 590 nm (urease), 405 nm (HRPO or alkaline phosphatase), and 450 (HRPO when TMB is used as the substrate) using a microtiter plate spectrophotometer.

For alkaline phosphatase-based assays, add 100 μl of 0.1 M EDTA to each well at the end of the incubation in order to stop the reaction. For HPRO assays using TMB substrate solutions, the reaction is terminated after incubation by the addition of 25 μl of sulfuric acid (1-3 M).
12. Plot absorbance versus ($\text{A}\beta$) antigen concentration $[\text{Ag}]$ on semilog paper for analysis of each dilution of enzyme-antibody conjugate. For working dilution of conjugate, choose a concentration that provides maximum sensitivity over a linear range of $[\text{Ag}]$ and minimum binding (below 0.05 absorbance units) to control antigens (synthetic peptide standards).
13. Serially dilute individual body fluid and controls or partially purified or purified $\text{A}\beta$ peptide preparations, as described in step 3. Use two columns per sample.

14. Repeat steps 4-6.
15. Shake out diluting buffer into a sink and add 0.1 ml per well of enzyme-antibody conjugate diluted in diluting buffer at the concentration determined in step 12.
- 5 16. Cover the plates with adhesive covers and incubate under the same conditions as used in step 9.
17. Repeat steps 10 and 11.
18. Compare the absorbance of the unknown to the standard curve for the enzyme-antibody conjugate concentration that was plotted in step 12 in order to determine the quantity of antigen expressed per volume of a body fluid or a sample of partially purified A β peptide.
- 10

Example 15: A method for bulk purification of A β peptide from biological fluids

The bulk purification of A β from biological fluids is best achieved with copper charged chelating-Sepharose (Pharmacia catalog no. 17-0575-01). The cysteine groups in the sample proteins are first methylated with a maleimide compound (e.g., N-methyl maleimide (Sigma catalog no. 930-88-1), about 1-10 mM, about 1 hour; also see Yomomote and KeKine, *Anal. Biochem.* 90:300-308 (1978)).

The methylated sample is then acidified by titrating pH to about 5.0 using about 1M sodium acetate, pH about 3.5, and the total NaCl concentration increased by about 500 mM with about 5M NaCl. The pH of the sample is monitored with a glass pH detector or pH indicator paper while sodium acetate is added dropwise with gentle stirring until the required pH is obtained.

The sample is then applied to a copper-charged chelating-Sepharose column (e.g., about 250 μ l bed volume for about 15 ml of CSF) as described above, in the section entitled Experimental Procedures. Equilibration buffer is about 500 mM NaCl about 50 mM MES pH about 5.0 and is used to wash the column. The Sepharose can be developed with about 500 mM NaCl, 50 mM EDTA, pH 8.0 alone and the eluate sampled for western blot analysis.

The treatment of 15 ml of CSF by this method enriched both soluble APP as well as 4.3 and 3.6 kD a species of A β (identified by an antibody that identifies an epitope in the first 16 residues of A β ; commercially available).

In order to bind copper or zinc, the peptide requires an intact domain from residues 6-28. 4G8 only recognized the two A β species and not APP, confirming that the APP captured by the Sepharose was post-secretase cleaved soluble APP. The use of specific anti-A β antibodies as described above on western blot analysis of these products can confirm the specificity of the ELISA immunoreactivity.

Example 16: A method for purification of A β peptide when the volume of the biological material is less than about 4 ml

The cysteine groups in the sample proteins are first methylated with a maleimide compound (e.g., N-methyl maleimide (Sigma catalog no. 930-88-1) about 1-10 mM, about 1 hour; also see Yomomote and KeKine, *Anal. Biochem.* 90:300-308 (1978)).

The methylated sample is then acidified by titrating pH to about 5.0 using about 1M sodium acetate, pH about 3.5, and the total NaCl concentration increased by about 500 mM with about 5M NaCl. The pH of the sample is monitored with a glass pH detector or pH indicator paper while sodium acetate is added dropwise with gentle stirring until the required pH is obtained.

Free copper-charged chelating-Sepharose slurry (about 60 μ l of about 50% v/v) is added to the sample.

Following centrifugation (preferably, low speed centrifugation (about 1,500 g, for about 3 minutes, equilibration buffer is used to wash the Sepharose pellet. Equilibration buffer is about 500 mM NaCl about 50 mM MES, pH about 5.0.

The Sepharose can be developed (protein is eluted by the addition of the eluting buffer) with about 500 mM NaCl, 50 mM EDTA, pH 8.0 alone and the eluate sampled for western blot analysis.

Having now fully described this invention, it will be understood by those of skill in the art that it can be performed within any wide range of equivalent modes of operation as well as other parameters without affecting the scope of the invention or any embodiment thereof.

5 All patents and publications cited in the present specification are incorporated by reference herein in their entirety.

What Is Claimed Is:

1. A diagnostic assay for detecting and/or quantifying A β peptide which may be present in a candidate solution, comprising:

5 (a) contacting the candidate solution with a solid support with a heavy metal cation immobilized thereon to capture A β peptide on the surface of the solid support, thereby forming a first complex which comprises solid support/heavy metal cation/A β peptide;

(b) blocking all exposed metal binding sites remaining after A β capture with a blocker;

10 (c) contacting the first complex, which has been passed through step (b), with an antibody specific for A β peptide to form a second complex which comprises solid support/heavy metal cation/A β peptide/antibody specific for A β peptide;

15 (d) labelling the second complex to form a detectable third complex which comprises solid support/heavy metal cation/A β peptide/antibody specific for A β peptide/label; and

(e) detecting the third complex, and quantifying A β peptide which may be present in the candidate solution.

20 2. A diagnostic assay for detecting and/or quantifying A β peptide which may be present in a candidate solution, comprising:

(a) contacting the candidate solution with a solid support with a heavy metal cation immobilized thereon to capture A β peptide on the surface of the solid support, thereby forming a first complex which comprises solid support/heavy metal cation/A β peptide;

25 (b) blocking all exposed metal binding sites remaining after A β capture with a blocker;

(c) contacting the first complex, which has been passed through step (b), with an antibody specific for A β peptide, called A β antibody, to form a second complex which comprises solid support/heavy metal cation/A β peptide/A β antibody;

30

(d) contacting said second complex with one or more anti-antibodies specific to the $A\beta$ antibody to form a third complex which comprises solid support/heavy metal cation/ $A\beta$ peptide/ $A\beta$ antibody/one or more anti-antibodies;

5 (e) labelling said third complex to form a detectable fourth complex which comprises solid support/heavy metal cation/ $A\beta$ peptide/ $A\beta$ antibody/one or more anti-antibodies/label; and

(f) detecting the fourth complex, thereby quantifying $A\beta$ peptide which may be present in the candidate solution.

10 3. A diagnostic assay as claimed in claim 1, wherein said heavy metal cation is selected from the group consisting of zinc (II) and copper (II) complexed to nitriloacetic acid.

15 4. A diagnostic assay as claimed in claim 2, wherein said heavy metal cation is selected from the group consisting of zinc (II) and copper (II) complexed to nitriloacetic acid.

5. A diagnostic assay as claimed in claim 3, wherein said antibody at step (c) is specific to $A\beta_{1-42}$ and does not cross react with $A\beta_{1-40}$.

6. A diagnostic assay as claimed in claim 3, wherein said antibody at step (c) is specific to $A\beta_{1-40}$ and does not cross react with $A\beta_{1-42}$.

20 7. A diagnostic assay as claimed in claim 4, wherein said antibody at step (c) is specific to $A\beta_{1-42}$ and does not cross react with $A\beta_{1-40}$.

8. A diagnostic assay as claimed in claim 4, wherein said antibody at step (c) is specific to $A\beta_{1-40}$ and does not cross react with $A\beta_{1-42}$.

25 9. A diagnostic assay as claimed in claim 5, wherein said antibody is labelled with a radioisotope.

10. A diagnostic assay as claimed in claim 6, wherein said antibody is labelled with a radioisotope.

11. A diagnostic assay as claimed in claim 7, wherein said antibody is labelled with a radioisotope.

5 12. A diagnostic assay as claimed in claim 8, wherein said antibody is labelled with a radioisotope.

13. A diagnostic assay as claimed in claim 5, wherein said enzyme is horseradish peroxidase.

10 14. A diagnostic assay as claimed in claim 6, wherein said enzyme is horseradish peroxidase.

15 15. A diagnostic assay as claimed in claim 7, wherein said enzyme is horseradish peroxidase.

16 16. A diagnostic assay as claimed in claim 8, wherein said enzyme is horseradish peroxidase.

17. A kit for carrying out the assay of claim 1 or 2, which comprises a carrier means compartmentalized in close confinement therein to receive one or more container means which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon and a second container means containing an antibody specific for A β peptide.

20 18. A kit as claimed in claim 17, wherein said heavy metal cation is selected from the group consisting of zinc (II) and copper (II) complexed to nitriloacetic acid.

19. A kit as claimed in claim 17, wherein said antibody is labelled with a radioisotope.

20. A kit as claimed in claim 17, wherein said enzyme is horseradish peroxidase.

5 21. A kit as claimed in claim 17, wherein said carrier means further comprises a third container means containing an anti-antibody which is specific for the A β antibody.

22. A kit as claimed in claim 21, wherein said anti-antibody is labelled with a radioisotope.

10 23. A kit for carrying out the assay of claim 1 or 2, which comprises a carrier means compartmentalized in close confinement therein to receive one or more container means which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon and a second container means containing a labelled antibody specific for A β peptide.

15 24. A kit as claimed in claim 23, wherein said heavy metal cation is selected from the group consisting of zinc (II) and copper (II) complexed to nitriloacetic acid.

20 25. A kit as claimed in claim 23, wherein the labelled antibody is labelled by a radioisotope.

26. A kit as claimed in claim 23, wherein said enzyme is horseradish peroxidase.

27. A kit for carrying out the assay of claim 1 or 2, which comprises a carrier means compartmentalized in close confinement therein to

receive one or more container means which comprises a first container means containing a solid support having a heavy metal cation immobilized thereon and a second container means containing an antibody specific for A β peptide bound to a labelled anti-antibody.

5 28. A kit as claimed in claim 27, wherein said heavy metal cation is selected from the group consisting of zinc (II) and copper (II) complexed to nitriloacetic acid.

 29. A kit as claimed in claim 27, wherein the labelled antibody is labelled by a radioisotope.

10 30. A kit as claimed in claim 27, wherein said enzyme is horseradish peroxidase.

 31. A method for purification of A β peptide from biological fluids which comprises:

- 15 (a) methylating cysteine groups of peptides in the biological fluid;
- (b) acidifying the biological fluid obtained from step (a);
- (c) applying the biological fluid obtained from step (b) to a copper-charged chelating-Sepharose column;
- 20 (d) washing the column with equilibration buffer to obtain an eluate solution; and
- (e) collecting the eluate solution, thereby obtaining purified A β peptide.

 32. A method for purification of A β peptide from biological fluids which comprises:

- 25 (a) methylating cysteine groups of proteins in the biological fluid;
- (b) acidifying the biological fluid obtained from step (a);

(c) adding to the biological fluid obtained from step (b), a free copper-charged chelating slurry to form a mixture;

(d) centrifuging the mixture obtained from step (c) to obtain a pellet;

5 (e) washing the pellet obtained from step (d) with equilibration buffer, thereby obtaining purified A β peptide.


10 33. A kit for carrying out the assay of claim 31 which comprises a carrier means compartmentalized in close confinement therein to receive one or more container means which comprises a first container means containing a copper charged chelating-Sepharose column and a second container means containing an antibody specific for A β peptide which may be used to confirm presence of purified A β peptide.

15 34. A kit for carrying out the assay of claim 32 which comprises a carrier means compartmentalized in close confinement therein to receive one or more container means which comprises a first container means containing free copper-charged chelating-Sepharose and a second container means containing an antibody specific for A β peptide which may be used to confirm presence of purified A β peptide.


***A Diagnostic Assay for Alzheimer's Disease: Assessment of
A β Abnormalities***

Abstract


5 The disclosed invention relates to assays for detecting and quantifying
A β peptide, using solid supports that are coated with heavy metal cations,
such as zinc (II) or copper (II) form of a nitriloacetic acid. Further,
diagnostic kits are described which are used to carry out the assays of the
present invention. An improvement in an assay for detection of A β peptide
is suggested which comprises forming a heavy metal cation/solid support
10 complex. The preferred heavy metal cations for this improvement are zinc
(II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for
bulk purification of A β peptides from biological fluids are taught.




- FIGURE 1a-




- FIGURE 1b-




- FIGURE 1c-




- FIGURE 1d-



- FIGURE 1e-




- FIGURE 2a-




- FIGURE 2b-

C




- FIGURE 2c-

a
214 nm abs. Sepharose SN




- FIGURE 3a-




- FIGURE 3b-


0.4 10 25 50 STD 200



- FIGURE 4a-




- FIGURE 4b-




- FIGURE 5-


Fraction filtered ($< 0.2 \mu$)




- FIGURE 6a-




- FIGURE 6b-




- FIGURE 6c-



- FIGURE 6d-




- FIGURE 7a -




- FIGURE 7b -


Stoichiometry Zn:Peptide




- FIGURE 7c -



- FIGURE 7d -




- FIGURE 8a-



- FIGURE 9 -

1	5	10	15	17	20	25	30	35	40	43
D	A	E	F	R	H	D	S	G	Y	E
V	H	H	Q	K	L	V	F	F	A	E
D	S	G	Y	E	V	H	H	Q	K	L
V	F	F	A	E	D	V	G	S	N	K
G	A	I	I	G	L	M	V	G	G	V
I	A	T								

- FIGURE 10 -



- FIGURE 11 -

Declaration for Patent Application

Docket Number: 0609.4110000

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled **A Diagnostic Assay for Alzheimer's Disease: Assessment of A β Abnormalities**, the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on April 18, 1997 (International filing date October 19, 1994);
as United States Application Number or PCT International Application Number 08/817,423; and
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Claimed	
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Application No.)	_____ (Country)	_____ (Day/Month/Year Filed)		
_____ (Application No.)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

_____ (Application No.)	_____ (Filing Date)
_____ (Application No.)	_____ (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/US94/11895</u> (Application No.)	<u>October 19, 1994</u> (Filing Date)	<u>Pending</u> (Status - patented, pending, abandoned)
_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)




Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Rudolph E. TANZI	
Inventor's signature	 6/24/97 ^{Date}
Residence	25 Strawberry Lane Canton, MA 02021
Citizenship	American
Post Office Address	
Full name of second inventor: Ashley I. BUSH	
Second Inventor's signature	 7/11/97 ^{Date}
Residence	91 SUMMER STREET #3, SOMERVILLE, MA 02143
Citizenship	Austrian
Post Office Address	
Full name of third inventor: Robert D. MOIR	
Third inventor's signature	 6/24/97 ^{Date}
Residence	28 Whittier Place, 3G, Boston MA 02114
Citizenship	Australian
Post Office Address	

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: TANZI, RUDOLPH E.
BUSH, ASHLEY I.
MOIR, ROBERT D.
- (ii) TITLE OF INVENTION: A Diagnostic Assay for Alzheimer's
Disease: Assessment of A β Abnormalities
- (iii) NUMBER OF SEQUENCES: 1
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
 - (B) STREET: 1100 NEW YORK AVENUE, NW, SUITE 600
 - (C) CITY: WASHINGTON
 - (D) STATE: DC
 - (E) COUNTRY: USA
 - (F) ZIP: 20005-3934
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To be assigned
 - (B) FILING DATE: Herewith (25-OCT-1999)
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/817,423
 - (B) FILING DATE: 04-AUG-1997
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: WO PCT/US94/11895
 - (B) FILING DATE: 19-OCT-1994
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: KIM, JUDITH U.
 - (B) REGISTRATION NUMBER: 40,679
 - (C) REFERENCE/DOCKET NUMBER: 0609.4110001/REF/JUK
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (202) 371-2600
 - (B) TELEFAX: (202) 371-2540

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr
35 40

[illegible]